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The e ffects  of various manoeuvres on the handling of 59pe labelled heat 
damaged red c e lls  (59pe HDRC) by the reticu loendothe lia l system were 
studied in ra ts . The study demonstrated that prior sa tu ra tion  of 
t ra n s fe r r in  w ith ora l carbonyl iron had l i t t l e  e ffe ct on splenic 
re le a se  o f 59pe but markedly inh ib ited  hepatic release. Splenic 
re lease  was, however, in h ib ite d  by the p r io r  adm in istra tion  of 
unlabelled HDRC. The combination of carbonyl iron and unlabelled HDRC 
exerted a sim ilar e ffe c t. When carbonyl iron was administered with 
unlabelled free haemoglobin, the pattern of 59Fe d is tr ibu tion  was the 
same as tha t observed when carbonyl iron was given alone. 59pe 
fe r r it in  was id en tif ie d  in  the serum after the administration of 59pe 
HDRC but the size of the fraction  was not affected by prior saturation 
of transfe rrin . S izing column analyses of tissue extracts from the 
spleen at various times after the administration of 59pe revealed a 
progressive s h if t  of 59pe from haemoglobin to fe r r it in ,  with only small 
amounts of 59pe present in a small molecular weight fraction . The 
small molecular weight fraction  was greater in hepatic extracts, with 
the difference being marked in  animals that had received prior carbonyl 
iro n . The increased hepatic re te n t io n  o f 59pe associated with 
saturation of transferrin  was reduced by a hydrophobic ferrous chelator 
(2,2' b ipyrid ine), by a hydrophilic fe r r ic  chelator (desferrioxamine) 
and by an e x tra c e llu la r  h yd ro p h ilic  f e r r ic  che la tor (d ie thy lene 
tr iam inepen ta -ace tic  a c id ) . Transmembrane iron transport did not 
appear to be a ra te  l im it in g  fa c to r in  iron  re le a se , s ince no
d iffe rences in 59pe membrane fractions were noted in the d iffe rent 
experimental settings. These findings are consistent with a model in 
which reticu loendothe lia l c e lls  release iron from catabolized red ce lls  
at a re la t iv e ly  constant ra te . When t ra n s fe r r in  is  saturated a 
s ig n ific an t proportion of the iron is  transported from the spleen to 
the live r in small molecular weight complexes or in fe r r it in .  While a 
saturated t ra n s fe r r in  has no e f fe c t  on the release of iron from 
reticu loendothe lia l c e lls ,  prior loading with HDRC does condition them 
to release less iron.
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PREFACE
Internal iron exchange involves a c ir c u it  in which iron is  released 
from c e lls  of iron procurement (gut mucosal c e lls ,  reticu loendothe lia l 
c e lls ,  hepatic parenchymal c e lls  and placental ce lls )  to the transport 
protein transferrin  and is  delivered to erythroid precursors and other 
active ly  growing c e lls .  Senescent red blood c e lls  are taken up by 
re t ic u lo e n d o th e lia l c e l ls  and the iron  so re leased  is  re cyc led  
(Bothwell et a l , 1979; Morgan, 1981; Huebers and Finch, 1987). While 
the processes involved in transferrin  iron delivery to erythroid and 
other c e lls  have been well characterized (Morgan, 1981; Huebers and 
Finch, 1987) l i t t l e  is  known of the mechanism of and factors regulating 
re t ic u lo e n d o th e lia l iron  metabolism and re le a se . Previous work 
in v o lv in g  the parentera l in fu s io n  o f elemental iro n  to  b lo ck  
transferrin  binding s ites  for iron has suggested that ce llu la r iron 
release is  inh ib ited  in the presence of a highly saturated transferrin  
( L ip s c h itz  e t a l , 1971c; Bergamaschi et a l , 1986). The current 
investigation aims to define the e ffects of various manoeuvres on 
in te rn a l iron  exchange. These manoeuvres inc lude  an increased 
transferrin  saturation after enteral carbonyl iron  adm in is tra tion , 
p r io r  adm in is tra tion  of heat damaged e ry th rocy tes , venesection, 
haptoglobin depletion and the administration of various c la sses  of 
chelators. Through these manoeuvres i t  is  hoped to obtain further 
ins ight in to  not only the regulation of internal iron exchange but also 
the nature of reticu loendothe lia l iron release. A knowledge of the 
mechanisms and nature of iron release may shed further lig h t on the
v
pathogenesis o f d iso rders o f iron  overload such as id io p a th ic  
haemochr omatosi s .
In chapter one, an overview of the factors involved in internal iron 
exchange is  presented. Chapter two deals w ith the methods and 
materials u t il iz e d  in th is  investigation. In chapter three the resu lts 
of the investigation are presented. Chapter four contains a discussion 
of the resu lts  obtained and concludes with a model of internal iron 
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CHAPTER ONE
AN OVERVIEW OF THE FACTORS INVOLVED IN INTERNAL IRON EXCHANGE
1
1 .1 . INTRODUCTION
Iron is  an essential element of nearly a ll liv in g  c e lls  and organisms 
and p a r t ic ip a te s  in  numerous m etabolic pathways (Morgan, 1981; 
Crichton and Charloteaux-Waters, 1987). The major portion of body iron 
in man is  in the iron porphyrin complexes haemoglobin, myoglobin and a 
v a r ie ty  of haem containing enzymes. There are also many non-haem 
enzymes which either contain iron or which require i t  as a co-factor 
(Bothwell e t a l , 1979). Haemoglobin and myoglobin function as 
revers ib le  binders of molecular oxygen, with haemoglobin transporting 
oxygen to resp ir ing  tissues and myoglobin serving as an oxygen store in 
skeletal muscle. The haem and non-haem enzymes p a r t ic ip a te  in  
reactions ranging from activation  of oxygen, nitrogen, and hydrogen to 
the control of electron flow through numerous bio-energetic pathways 
(Bothwell et a l , 1979).
Iron is  also stored w ith in the body as fe r r it in  and haemosiderin which 
are designed for holding iron in a re la t iv e ly  non-reactive form. About 
35 to 40 mg per kg of tota l body iron is  present in the functional iron 
compounds in man and depending on the iron status of the ind iv idua l, 
between 0 and 20 mg per kg of total body iron may be present in the 
storage iron compartment of man (Bothwell et a l , 1979). In total the 
iron content of man is  approximately 50 mg per kg.
Despite the fact that iron is  the fourth most abundant element and the 
second most abundant metal in the earth 's crust, in the environment
2
iron ex ists almost exclusively in the oxidised state, a factor that 
greatly reduces it s  a c c e s s ib ilty  (Bothwell et a l , 1979). Man in  
particu la r finds iron d if f ic u l t  to obtain and absorbs each day only 1­
2% of the amount that other mammals achieve (Finch and Huebers, 1982). 
For th is  reason the body exhib its great economy in it s  handling of 
iron, and internal iron k in e t ic s  are la rg e ly  concerned w ith the 
continuous red is tr ibu tion  of iron w ith in the body.
Internal iron exchange involves the c ir c u it  of iron release from ce lls  
o f iron  procurement, namely gut mucosal c e lls ,  reticu loendothe lia l 
c e lls ,  hepatic parenchymal c e lls  and placental c e lls ,  to the transport 
p ro te in  tran s fe rr in , the delivery of transferrin  iron to erythroid 
precursors and other active ly  growing c e lls  and f in a lly  the recycling 
of e ry th ro id  c e l l  iron  by the re t ic u lo e n d o th e lia l and hepatic 
parenchymal ce ll (Bothwell et a l , 1979; Morgan, 1981; Huebers and 
F inch , 1987). F e r ro k in e t ic  analyses have shown that the largest 
fraction  of plasma iron (24. mg per day) is  destined for the synthesis 
of haemoglobin in  developing erythrocytes, w h ilst about 5 mg per day is  
exchanged between transferrin  and parenchymal tissues (Bothwell et a l , 
1979).
The factors involved in  internal iron exchange are presented in th is 
chapter. Plasma transport of iron is  described in section 2. In 
section 3, iron delivery to erythropoietic c e lls ,  the regulation of 
iron uptake by e ry th ro p o ie t ic  c e l ls  and ery th rocyte  ageing are 
d is c u s s e d .  S e c t io n  4 d e a ls  w ith  the  i r o n  e n t r y  in t o
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r e t i c u lo e n d o t h e l ia l  c e l l s ,  haem oglobin d eg rada tio n  in  the 
reticu loendothe lia l c e ll and iron metabolism in the reticu loendothe lia l 
c e l l .  Hepatocyte iron uptake is  covered in  section 5 and the proteins 
of iron storage are d iscussed in  section  6. Iron re le a se  from 
reticu loendothe lia l c e lls  and hepatocytes is  discussed in  section 7, 
and the low molecular weight iron pool is  covered in  section  8. 
Section 9 deals with chelatable iron and chelating agents.
1.2. PLASMA TRANSPORT OF IRON
1.2.1. Introduction
Iron is  the fourth most abundant metal in the earth 's crust (Bothwell 
et a l , 1979). However, iron ex ists almost exclusively in the fe r r ic  
state in the external environment. Its  existence in the fe r r ic  state 
is  a factor which greatly reduces the a c ce ss ib ility  of iron to liv in g  
organisms. This is  because fe r r ic  iron is  unstable in solution at 
neutral pH and is  rap id ly  hydrolysed to in s o lu b le  or so lub le  but 
b io lo g ica lly  unavailable forms of fe r r ic  hydroxide . This problem has 
been overcome by l iv in g  organisms in  th e ir  development of iron  
complexing agents. These agents serve to so lu b ilize  iron in the 
ex trace llu la r f lu id  and are involved in the transport and delivery of 
iron to c e lls .
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In ve rteb ra tes , over 95% of plasma iron is  normally bound to the 
transport protein apotransferrin which provides the mechanism by which 
the needs of the individual body tissues for iron can be sa tis fied  
(Bothwell et a l , 1979). The remainder of plasma iron  is  known 
co lle c t iv e ly  as non-transferrin bound iron and is  complexed to other 
iron compounds which are present in plasma in much smaller quantities 
than transfe rrin . Such compounds include haptoglobin, haemopexin and 
fe r r it in .  Non-specific binding of iron to plasma proteins and low 
molecular weight complexes, as occurs in s ituations where the spec ific  
iron binding s ites  of t ra n s fe r r in  are saturated w ith iro n , a lso  
constitutes non-transferrin bound iron.




Transferrin is  a glycoprotein with an e llip s o id  shape (Morgan, 1981; 
Huebers and Finch, 1987). I t  consists of a single polypeptide chain 
tha t has two s im ila r  domains, each of which constitutes ha lf the 
molecule and each of which contains one iron binding s ite  (Morgan, 
1981). The 2 binding s ites are the acid la b ile  N terminal and the acid 
stable C terminal s ite  (Huebers and Finch, 1982). The polypeptide 
chain is  composed of 678 amino acid residues which, together with 2 N-
5
linked oligosaccharide chains gives i t  a molecular weight of 80000 D 
(MacG illivray et a l , 1983). The function of these two oligosaccharide 
chains, which are loca lized  to the carboxy ha lf of the transferrin  
molecule, is  unknown (Morgan, 1981; Huebers and Finch, 1987).
The two iron binding s ites  of transferrin  each bind iron independently 
(Morgan, 1981; Huebers and Finch, 1987). The transferrin  pool is  not 
homogenous and transfe rrin  c ircu la tes in plasma and in te r s t it ia l f lu id  
in four forms depending on i t s  degree o f sa tu ra tion  w ith iro n . 
Transferrin may ex is t as the d ife r r ic - ,  monoferric a-, monoferric b-, 
or apotransferrin form. These forms may ex ist simultaneously in plasma 
(Bothwell et a l , 1979; Finch and Huebers, 1982; Huebers et a l , 1984). 
There is  no evidence that the demonstrable differences in in v itro  
behaviour of the two binding s ites  on transferrin  have any sign ificance 
insofar as physiologic iron transport is  concerned (Van der Heul et a l , 
1981; Huebers et a l , 1981; Delaney et a l , 1982). D ife r r ic  
transferrin  does however appear to deliver iron more e ff ic ie n t ly  to 
t is su e s  than does m onoferric tra n s fe rr in  (Huebers et a l , 1983a). 
Loading of transferrin  with iron appears to occur at random so that i t  
is  possible to predict the d is tribu tion  of d ife r r ic ,  monoferric and 
unloaded molecules at various saturations of transfe rrin  w ith iron  
(Finch and Huebers, 1982).
Transferrin is  sim ilar to two other iron-binding glycoproteins, namely 
la c to fe rr in  and conalbumin. A ll three proteins have sim ilar molecular 
weights, length of polypeptide chains, carbohydrate moieties, iron­
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binding s ites and some shared amino acid sequences (Aisen and Leibman, 
1972; Metz-Boutigue et a l , 1984). However, they d iffe r in th e ir  
immunologic p rop e rt ie s , their function and their s ites of highest 
concentration. The maximal iron-binding capacity of these d iffe ren t 
proteins is  highly pH dependent. Whereas transferrin  binds iron most 
avid ly at a neutral to a lka line  pH, conalbumin binds iron  at an 
a lka line  pH and la c to fe rr in  binds iron at an ac id ic  pH (Montreuil et 
a l , 1960; Weinberg, 1984). L a c to fe r r in  cannot provide iron  to 
re t ic u lo c y te s  (Brock and Esparza, 1979). When present in plasma, 
d ife r r ic  la c to fe rr in  is  c lea red  by re t ic u lo e n d o th e lia l c e l ls  and 
hepatocytes.
1.2.2.2. Transferrin synthesis
The p rinc ipa l s ite  of serum transfe rrin  production is  the hepatocyte 
(Morgan, 1981). The other major s ite  of transferrin  production is  the 
la c ta t in g  mammary gland (Jordan and Morgan, 1969). Regulation of 
transferrin  production has been close ly  linked with the status of iron 
stores. Transferrin production is  increased with iron store depletion 
and decreased with iron store rep le tion  (L ipsch itz et a l , 1974).
I t  has not yet been elucidated exactly what molecular events regulate 
transferrin  gene expression in iron deficiency (Idzerda et a l , 1986). 
Studies on the liv e rs  of iron de fic ien t chicks and ra ts  showed them to 
contain elevated leve ls of transferrin  mRNA (Mcknight et a l , 1980a; 
Idzerda et a l , 1986). In ra t hepatocytes, the elevated levels of
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transfe rrin  mRNA were found to re su lt from induction of transferrin  
gene transcrip tiona l a c t iv ity  ra ther than from the re g u la t io n  of 
translationa l a c t iv ity  (Idzerda et a l, 1986).
Stimulation of transferrin  synthesis also occurs in  pregnancy and 
during the administration of oestrogens (Bothwell et a l , 1979; Morgan, 
1981). The e ffects of oestrogens a lso  appear to be re la te d  to 
increased mRNA tra n s c r ip t io n  (Mcknight et a l , 1980b). Plasma 
transferrin  concentration is  decreased in protein depleted s ta te s , 
probably as a re su lt  of depletion of the amino acid protein synthesis 
pool (Morgan, 1981).
1.2.2.3. Iron exchange with transfe rrin
As mentioned above, there are two spec ific  metal binding s ite s  on 
transfe rrin , each of which binds one iron atom (Morgan, 1981). The 
binding o f iron  to t ra n s fe r r in  re q u ire s  the a sso c ia t io n  of the 
t ra n s fe r r in  molecule with carbonate or bicarbonate anions (Morgan, 
1981). These anions function to secure the iron in to  place in the 
transfe rrin  molecule by serving as a bridging ligand between iron and 
the protein (Huebers and Finch, 1987). The anions also appear crucia l 
in iron release from transfe rrin  (Egyed, 1973). While in v itro  studies 
appear to ind icate that both ferrous and fe r r ic  iron serve as the 
source of transferrin  iron, i t  is  s t i l l  unknown whether iron in vivo is  
presented to the transferrin  molecule in the fe r r ic  or the ferrous form 
(Crichton and Charloteaux-Wauters, 1987; Huebers and Finch, 1987).
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Iron binding by transfe rrin  in v itro  is  pH dependent and is  maximal 
above pH 7 (Morgan, 1981). While iron is  bound to transfe rrin , the 
d iffu s ion  properties and rate  of penetration of iron through ce llu la r 
membranes such as the cap illa ry  wall have the characteristic  features 
of it s  carrying protein transfe rrin  rather than the features of a small 
molecule or ion. Thus, when iron is  bound to transfe rrin , iron loss 
from the body by passage through surface membranes, as occurs in the 
kidney is  greatly reduced. Another major consequence of transferrin- 
iron binding is  that the free iron concentration in body flu id s  is 
extremely low, thereby avoiding the harmful e ffects of adsorption of 
iron to c e ll membranes. In addition, transferrin  minimizes iron losses 
from the body by depositing surplus iron in tissues designed for iron 
storage (Bothwell et a l , 1979).
As a r e s u lt  o f the high a f f in i t y  o f t ra n s fe r r in  fo r iron , the 
spontaneous d issociation  of iron from transferrin  cannot occur at a 
s ig n ific a n t rate (Aisen and Leibman, 1968). The consequence of th is is 
that either the whole transfe rrin -iron  complex must be broken down to 
supply iron to c e lls ,  or special mechanisms for the detachment of iron 
from transferrin  must ex is t. The mechanism of iron delivery to c e lls  
by transferrin  has been described in  deta il recently , and is  discussed 
in section 1.3.1. A review of current knowledge on the subject of 
iron release from reticu loendothe lia l and hepatic c e lls  to transferrin  
is  presented in section 1.7. The experimental findings of th is  study 
with regard to th is  subject are presented in  chapter 4.
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1 .2 .2 .4 .  The r o le  o f  t r a n s f e r r in  in  in t e s t in a l  i r o n  a b so rp t io n
Besides being found in serum, mammalian transferrins have been found at 
other s ite s  in the body. One such s ite  is  the small in testine, where 
transfe rrin  is  thought to be involved in the process of inorganic iron 
absorption.
Transferrin has been found in  the lumen of the small in testine , on the 
mucosal surface and inside the mucosal c e l ls  of the duodenum and 
jejunum (Huebers et a l , 1976). The source of th is  transferrin  is
uncertain. I t  has been claimed that small in te s t in a l ep ithe lium  
contains an iso transfe rr in  which is  secreted in to  the gastrointestinal 
lumen in a sim ilar manner to the secretion of siderophores by bacteria 
(Huebers et a l , 1976; 1983b; Pollack and Lasky, 1976). The iron-
transferrin  complex formed in the in tes tina l lumen may then enter the 
in tes tin a l epithelium by a process of receptor mediated endocytosis. 
This hypothesis is  supported by the find ing of a high molecular weight 
elutable factor in the lumina of iron de fic ien t ra ts which appears to 
promote iron absorption (Huebers et a l , 1976). A further poss ib ilty  on 
the source of the transfe rrin  found intra lum ina lly in the intestine is  
that i t  may be derived from b il ia ry  secretion of plasma transferrin .
Recent evidence against the mucosal production of an iso transferrin  
involved in  in tes tin a l iron absorption has been the in a b i l i t y  to 
demonstrate transferrin  mRNA in gastro intestina l mucosal c e lls  (Idzerda 
et a l , 1986).
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Further doubt on the ro le  of transferrin  in  in testina l iron absorption 
has recently been cast by the in a b il ity  to demonstrate with the use of 
immunocytochemical tests the presence of transferrin  receptors on the 
luminal surface of mucosal c e lls  (Parmley et a l , 1985) and on the brush 
border of mucosal c e lls  (Banerjee et a l, 1986). The in a b ility  to 
demonstrate an enhancing e ffe c t of transferrin  on iron absorption in 
achlorhydric subjects (Bezwoda et a l, 1986) may be seen as further 
evidence disputing the ro le  played by mucosal t ra n s fe r r in  in  iron  
absorption.
While there is  evidence disputing the d irect ro le  transferrin  may play 
in in tes tin a l iron absorption, transferrin  may function in an as yet 
undetermined manner to increase iron absorption in iron deficiency. 
Th is hypothesis is  supported by the f in d in g  o f an in c re a se d  
concentration of in tes tina l transfe rrin  in ra ts when iron deficiency is 
present (Hal 1 iday et a l , 1976) and by the find ing of an increased 
concentration of b il ia ry  transfe rrin  in iron de fic ien t ra ts (Huebers et 
a l,  1983b).
1.2.2.5. The transferrin  receptor
In it s  delivery of iron to c e lls ,  iron carrying transferrin  binds to 
sp ec ific  receptor s ites on the c e ll membrane. The transferrin  receptor 
is  a transmembrane glycoprotein which is  coded for on human chromosome 
3q 21-25 (Yang et al , 1984; Rabin e t a l , 1985). I t  conta ins 
approximately 5% carbohydrate by weight (Seligman et a l, 1979). The
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recepto r is  a dimer w ith  a disulphide linkage and each component 
monomer is  capable of binding a d ife r r ic  transferrin  molecule (Morgan, 
1981; Huebers and Finch, 1987). Each monomer has a molecular weight 
of approximately 90000 D ( Enns and Sussman, 1981). The transferrin  
receptor has a small in tra ce llu la r  amino terminal domain and a large 
ex trace llu la r car boxy terminal domain consisting of 672 amino acids 
(Schneider et a l , 1984). Like other receptor proteins, the transferrin  
receptor is  amphipathic.
The binding process of transferrin  carrying iron to the transferrin  
receptor is  very e ff ic ie n t .  Binding of transfe rrin  to it s  receptor is  
calcium dependant (Hemmaplardh and Morgan, 1977), and maximal at pH 7.8 
(van Bockxmeer et a l , 1978).
The iron status of the transfe rrin  molecule exerts an important e ffect 
on the a f f in ity  of the molecule for it s  receptor. The transferrin  
receptor has a very high a f f in ity  for d if fe r ic  transferrin  ^Trowbridge 
et a l , 1984). Monoferric transferrin  and apotransferrin respectively 
have less a f f in ity  for the transfe rrin  receptor at physiological pH 
(Huebers et a l , 1983a).
The development o f monoclonal antibodies with sp e c if ic ity  for the 
transferrin  receptor has allowed for the immunological demonstration of 
transfe rrin  receptors on ce ll surfaces (Schneider et a l, 1982), and 
transferrin  receptors have been found to be d istributed on almost a ll 
human c e l l  types evaluated. Receptor a f f in ity  for transferrin  by
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d iffe ren t tissues of an organism appears to be constant (Trowbridge et 
a l, 1984).
Regulation of transferrin  receptor expression by c e lls  is  not fu lly  
understood. Transferrin receptor expression on ce ll membranes appears 
to be regu la ted  la rge ly  by the in tra ce llu la r  chelatable iron pool 
(Bridges and Cudkowicz, 1984; Bottomley et al , 1985). Evidence
supporting  th is  f in d in g  is  tha t increased t ra n s fe r r in  receptor 
expression occurs when the iron supply to c e l ls  is  dim inished by 
chelating agents or by growing c e lls  in iron de fic ien t media (Bottomley 
et a l , 1985). I t  appears that the synthesis of the t ra n s fe r r in  
receptor is  under t ra n s c r ip t io n a l co n tro l.  However recent data
suggests that iron may down-regulate transfe rrin  receptor expression by 
a mechanism s im ila r  to the one by which i t  induces increased 
translation  of fe r r it in  mRNA (Casey et a l , 1988). What is  clear is  
th a t non r e p l ic a t in g  c e l ls  appear to have a s tab le  number of 
t ra n s fe r r in  re cep to rs . In con tra s t to th is ,  c e l ls  undergoing 
m u ltip lica tion  markedly increase the ir number of transferrin  receptors 
(Trowbridge and Omary, 1981). The find ing of so many t ra n s fe r r in  
receptors on rap id ly  growing c e lls  and on malignant c e lls  ra ises the 
p o s s ib ility  that the transfe rrin  receptor may play a r o le  in  host 
defence against neoplasia. The exact mechanism by which th is  may occur 
has not been fu l ly  elucidated. The increase in transferrin  receptor 
number on m u lt ip ly in g  c e l ls  occurs because tra n s fe rr in -ce ll- iro n  
in teraction  is  important in the regulation of c e l lu la r  growth and 
p ro life ra t io n . Evidence for th is  has been the find ing that transferrin
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is  e ssen tia l fo r cu ltu red  c e l ls  to grow in serum-free conditions 
(Barnes and Sato, 1980). The p ro life ra t io n  of cu ltu red  c e l ls  is  
in h ib ite d  i f  th e ir  receptors are blocked by monoclonal antibodies 
sp e c ific  for transferrin  binding s ite s , as well as i f  the c e lls  are 
deprived of transfe rrin . I t  would appear that the transferrin  receptor 
interaction  is  the important component in growth regulation and that 
the e ffe c t may be independent of the iron content of transferrin  (May 
and Cuatrecasas, 1985).
1.2.3. Non-transferr in-bound iron
1.2.3.1. Haptoglobin and haemopexin
Haemoglobin, present in the plasma as the re su lt  of intravascular 
haemolysis or the ly s is  of red c e ll precursors in the marrow, normally 
co n s t itu te s  approximately 2% of plasma iron. This haemoglobin is  
complexed in the plasma by a spec ia l haemoglobin c a r r ie r  c a lle d  
haptoglobin which is  synthesized prim arily in the liv e r (Bothwell et 
a l , 1979). In the plasma, haemoglobin d issociates into dimers and each 
haptog lob in  molecule binds two of these dimers (Nagel and Gibson, 
1971). The binding of haemoglobin to haptoglobin is  irreve rs ib le , and 
s in ce  haptog lob in  production is  not stepped up in response to an 
increased haemoglobin load, the plasma concentration of haptoglobin 
prov ides an in d ic a t io n  of the amount o f ongoing in travascu la r 
haemolysis (Bothwell et a l , 1979). Haemoglobin bound to haptoglobin is
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transported to the liv e r where i t  is  taken up by hepatocytes (see 
section 1.5.3.1.).
When haemoglobinaemia exceeds the haptoglobin binding capacity of 
plasma, oxidation of the iron in the haemoglobin molecule permits the 
haem moiety to d issociate from it s  polypeptide chain and a second iron 
transport protein present in  plasma ca lled  haemopexin binds the haem 
which is  liberated (Bothwell et a l , 1979). Haemopexin is  synthesized 
in the liv e r and the haem haemopexin complexes are also removed from 
the c ir c u la t io n  by hepatocytes (see sec tion  1 .5 .3 .1 .) .  Since 
haemopexin production, lik e  haptoglobin production, does not increase 
in response to an increased demand, it s  plasma concentration has a 
sim ilar s ig n if ic a n ce  to the plasma concen tra tion  o f haptoglob in 
(Muller-Eberhard et a l , 1968). I f  the haemopexin is  exhausted, haem 
binds to albumin un til fresh haemopexin is  synthesized (Bothwell et a l , 
1979).
1.2.3.2. Serum fe r r it in
Small amounts of fe r r it in  (usually less than 1% of serum iron) are 
found c ircu la ting  in the plasma of normal ind iv idua ls (Bothwell et a l , 
1979). W h ile  under normal circum stances the serum f e r r i t in  
concentration is  a function of the size of the body iron stores (Finch 
et a l , 1986), i t s  fu l l  physiological s ign ificance is  not yet en tire ly  
understood.
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Serum f e r r i t i n  is  discussed more fu lly  in section 1.6.3. and the 
hepatic clearance of serum fe r r it in  is  discussed in section 1.5.3.2.
1.2.3.3. Low molecular weight plasma iron complexes
While in normal ind iv idua ls the plasma concentration of iron complexed 
w ith  low m olecular weight compounds such as ascorbate, carbonate, 
certa in  amino acids and plasma proteins such as albumin is  extremely 
small, much higher concentrations of tota l iron in plasma in th is  form 
have been found c ircu la t in g  in  patients with severe iron  overload 
(Hershko et a l , 1978b; Anuwatanakulchai et a l , 1984; Gutteridge et 
a l , 1985; Wang et a l , 1986). This may occur as a re su lt  of saturation 
of the binding capacity of transfe rrin  (Brissot et a l , 1985). While 
hepatic t ra n s fe r r in  recep to rs  have been found to be reduced in 
haemochromatosis, the underlying defect remains unknown (Sciot et a l, 
1987). The highly e f f ic ie n t  hepatic uptake process of th is  form of 
iron (discussed in  section 1.5.3.3.), together with the high plasma 
leve ls found in  haemochromatosis have led many researchers to suggest 
that the low molecular weight complexes not bound to transferrin  may be 
prim arily responsible for the hepatic iron loading and tox ic ity  that 
characterizes haemochromatosis and other iron loading states (Hershko 
et a l , 1978b; B rissot et a l , 1985; Wright et a l , 1986; 1988).
Low molecular weight iron complexes have been shown to promote the 
formation of free hydroxyl rad ica ls  and to accelerate the peroxidation 
of membrane lip id s  in v itro  (Gutteridge et a l , 1985). The a v a ila b ility
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of th is  non-transferrin plasma iron for chelation by therapeutic agents 
such as desferrioxamine is  important as i t  serves as a route whereby 
the le ve l o f iron  sto res can be reduced and also as a means of 
decreasing the amount of iron in  iron-loaded c e l ls  (Jacobs, 1977; 
Hershko and Weather a l l ,  1988).
1.3. THE ERYTHROCYTE
1.3.1. Iron delivery to erythropoietic c e lls
1.3.1.1. Introduction
As d iscussed prev iously , the major function of transferrin  is  the 
transport of iron from wherever i t  enters the plasma to the developing 
erythroblasts of the marrow. Iron is  u t il iz e d  by the erythroblasts in 
haemoglobin synthesis (Fairbank and Beutler, 1983). On morphological 
grounds, a number of stages in the development of the erythrocyte have 
been described. The successive morphological a lterations observed as 
the  p ro e ry th rob la s t develops in to  the ery th rocy te  r e f le c t  the 
functional spec ia liza tion  of these c e lls  and their maturation (Bessis 
et a l,  1983). Studies u t i l iz in g  rad io labe lled  iron have shown that 
iron is  taken up from the plasma by a ll erythrocyte precursors in the 
bone marrow (Myhre, 1964; Ward et a l , 1966). Maximal iron uptake is  
observed at the ea r lie r stages of red ce ll precursor development. 
However, even after loss of the nucleus, the immature erythrocyte or
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re ticu locy te  as i t  is  known is  s t i l l  able to u t i l iz e  plasma iron for 
haemoglobin synthesis (Jandl e t al , 1959). The m a jo r ity  of 
investigations concerned with the mechanism of iron exchange between 
t r a n s f e r r in  and e r y th r o id  c e l l s  have been perform ed us ing  
re ticu locy tes. This is  due to the fact that these c e lls  are obtained 
with re la t iv e  ease from peripheral blood. However, most of the data 
presented a lso  ap p lie s  to nucleated e ry th ro id  c e l ls  and to non 
erythroid c e lls .
While in i t ia l  studies suggested that transferrin  iron was delivered to 
and released at the erythroblast membrane (Jandl and Katz, 1963), a 
great deal of evidence now indicates that the release of iron from 
transferrin  occurs w ithin the c e ll i t s e l f .  The uptake of transferrin  
iron by receptors and i t s  in tra ce llu la r  cycle have been described in 
deta il recently  (Dautry-Varsat et a l , 1983; Klausner et a l , 1983).
The steps invo lved  in  the uptake o f tran sfe rrin -bound  iron  by 
re ticu locy tes and nucleated erythroid precursors are: (1) transferrin
binding to sp e c ific  receptors on the ce ll membrane, (2) transferrin  
entry in to  the c e l l ,  (3) iron release from transferrin  and (4) release 
of transferrin  from the c e l l .
1.3.1.2. Transferrin-receptor interaction
D ife rr ic  transfe rrin  binds to sp e c ific  transferrin  receptors on the 
ce ll surface. The nature of these receptors has already been dealt
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w ith  (see sec tion  1 .2 .6 .) .  The b ind ing  of transferrin  to the 
transferrin  receptor is  revers ib le  and exhib its saturation k in e t ic s  
(van Bockxmeer et a l , 1978; van Bockxmeer and Morgan 1977; 1979).
Approximately 80000 t ra n s fe r r in  molecules can be bound by each 
r e t ic u lo c y te .  As re t ic u lo c y te s  mature, there is  progressive 
disappearance of functional transferrin  receptors (Pan and Johnstone, 
1984).
As mentioned previously, the binding of transferrin  to it s  receptor is  
dependent on pH, the presence of calcium ions and the iron content of 
t r a n s f e r r in .  Ev idence  fo r  t h is  in c lu d e s  the f in d in g s  that 
apotransferrin has a lower a f f in ity  for the transferrin  receptor than 
does d i f e r r ic  t r a n s fe r r in  (Morgan, 1981), and that incubation of 
re ticu locy tes with calcium chelators causes inactivation  of receptors 
and lo ss  of iron  uptake (Hemmaplardh and Morgan, 1977). Further 
evidence that ce llu la r  uptake of iron from transfe rrin  is  dependent on 
the b ind ing  o f t ra n s fe r r in  to  the t ra n s fe r r in  receptor is  that 
fo llow ing the p ro teo ly tic  d igestion  of re t ic u lo c y te s ,  there is  a 
reduction of transferrin  binding to receptors and a decrease in the 
rate of iron uptake by the c e lls  (Hemmaplardh and Morgan, 1976).
1.3.1.3. Di fe r r ic  transfe rrin  in te rna liza tion
Once bound to the transfe rrin  receptor on the ce ll surface, d ife r r ic  
transfe rrin , together with it s  receptor, is  taken into the ce ll by a 
process of receptor mediated endocytosis (Morgan, 1981; May and
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Cuatrecasas, 1985; Wileman et al 1985; Bomford and Munro, 1985; 
Stahl and Schwartz, 1986). b ind ing  to the ce ll membrane appears to be 
e ssen t ia l fo r endocytosis to occur, since other proteins such as 
albumin and IgG for which there are no sp ec ific  binding s ites are not 
endocytosed by reticu locy tes (Hemmaplardh and Morgan, 1977).
Substances other than transferrin  are also taken into c e lls  by receptor 
mediated endocytos is . These inc lude  c h o le s te ro l,  vitam in B^2> 
epidermal growth factor, p la te le t-d e r iv ed  growth fa c to r ,  in s u l in ,  
gonadotrophins, toxins such as diphtheria and pseudomonas toxin, and 
viruses such as influenza (Stahl and Schwartz, 1986). The receptors 
for these molecules are found in  c la th rin  coated p its , c la th rin  being a 
protein that supports the receptors in the c e ll membrane. I t  appears 
tha t a number o f ligands enter the c e ll via the same coated p it  
(Carpentier et a l , 1982).
Once the ligand has bound to it s  receptor, the c la th rin  coated p it  
invaginates, loses the c la th rin  and forms a prelysosomal endosome, 
known as a receptorsome. The receptorsome is  then transported by 
sa ltatory motion w ith in the c e l l  cytoplasm along m icrotubule and 
microfilament tracts (May and Cuatrecasas, 1985). The process appears 
to be energy dependent and is  also sensitive to changes in temperature. 
Almost no endocytosis occurs at 4°C, with endocytosis increasing as the 
temperature is  ra ised. Endocytosis is  inh ib ited  at temperatures above 
40°C (Morgan, 1981). The mechanism responsible for th is  may be the 
denaturation of membrane prote ins invo lved  in  endocytos is . That
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t ra n s fe r r in  endocytosis is  blocked by a variety of inh ib ito rs of 
ce llu la r metabolism such as dinitrophenol and rotenone is  evidence that 
endocytosis is  linked to a supply of metabolic energy (Morgan, 1981).
Factors inducing in te rna liza tion  of the transferrin  receptor, other 
than t ra n s fe r r in ,  include monoclonal antibodies to the transferrin  
receptor (McArdle and Morgan, 1984) and the phorbal esters. These 
e s te rs , which are s t ru c tu ra lly  unre lated  to tra n s fe r r in , induce 
in te rna liza tion  of the transferrin  receptor, even in the absence of 
transferrin  (May et a l , 1984; 1985). These esters are thought to act
by stimulating the production of calcium dependent protein kinase C. 
P ro te in  kinase in  turn appears to phosphorylate the transferrin  
receptor.
May and coworkers (1985) showed that cytoskeleton inh ib ito rs  could 
in h ib it  transferrin  receptor in te rna liza tion  induced by phorbol esters 
without in h ib it in g  transfe rrin  receptor phosphorylation. This suggests 
that phosphorylation of the transfe rrin  receptor is  not the only factor 
involved in  stimulating receptor endocytosis. Endocytosis can also be 
blocked by microtubular and microfilament inh ib ito rs  such as the vinca 
a lk a lo id s  and co lch ic ine (Hemmaplardh et a l , 1974). The foregoing 
discussion indicates that transferrin  receptor in te rna liza tion  involves 
complex interactions between ce ll membranes, c la th rin  coated p its , the 
cy to ske le ton , m icrotubu les and m icro filam ents and the enzymes 
regu lating phosphorylation of these structures.
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1 .3 .1 .4 .  Iron  r e le a s e  from  t r a n s f e r r in
After endocytosis of the d ife r r ic  transferrin  receptor complex, the 
in te r io r of the endocytic vesic le  becomes a c id if ie d . This occurs by an 
active protonation process which is  energy dependent (Wileman et a l , 
1985). The a c id if ie d  vesic le  is  known as the compartment of uncoupling 
of recepto r and ligand  (CURL) (G o ldste in  e t a l , 1979). Iron 
d is so c ia te s  from transferrin  in  the a c id if ie d  vesic le , leaving the 
iron-free apotransferrin in the vesic le . The e f f ic ie n t  translocation of 
iron through the membrane barrier between the s ite  of i t s  release from 
transfe rrin  in the a c id if ie d  vesic le  and the s ite  of it s  u t il iz a t io n , 
is  by a re c e n t ly  described high a f f in i t y  c a r r ie r  mediated iron 
transport system present in  the membrane of the vesic le  (Egyed, 1988).
Iron d e liv e ry  to c e l ls  can be in h ib ite d  by in terfering  with the 
a c id i f ic a t io n  of the endocytic v e s ic le .  Weak bases such as 
chloroquine, ammonium ch loride and methylamine d iffuse across membranes 
in to  c e l ls  in  th e ir  uncharged, l i p id  so lu b le  forms. They can 
accumulate in the endocytic vesic le  where they become protonated. This 
in turn can buffer the endocytic vesic le  against a c id if ic a t io n  (Wileman 
et a l , 1985).
Iron delivery to c e lls  can also be disturbed by inh ib ito rs  of energy 
metabolism. The mechanism of th is  also appears to be interference with 
endosomal a c id if ic a t io n  (K a ilis  and Morgan, 1974). An example of such 
a substance is  the metabolic inh ib ito r 2,4 d in itro-pheno l.
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1 .3 .1 .5 .  T r a n s fe r r in  r e le a s e  from  the  c e l l
The endocytosis of most receptor-ligand complexes re su lts  in  the ir 
in tra ce llu la r catabolism w ith in secondary lysosomes which are formed as 
a re su lt  of the fusion of the endocytic vesicle  with in tra ce llu la r 
lysosomes. An example is  that of epidermal growth factor whose 
receptor undergoes digestion in the endocytic vesicle  (Wileman et a l , 
1985). This is  not the case for transfe rrin  and it s  receptor which are 
recycled. The variable pH dependent a f f in i t i e s  o f d i f e r r ic -  and 
a p o tra n s fe r r in  fo r the t ra n s fe r r in  recepto r is  fundamental to 
transfe rrin  recyc ling  through the c e l l .
As mentioned, a c id i f ic a t io n  o f the endocytic vesic le  resu lts  in 
d is s o c ia t io n  o f iron  from t r a n s fe r r in ,  leav ing  the iro n  fre e
apotransferr in in  the vesic le . Apotransferr in has a low a f f in ity  for
the transfe rrin  receptor at physiological pH. However, in the acid ic 
environment of the endocytic ves ic le , apotr ansferr in has very high 
a f f in ity  for the receptor. This has been shown in  hepatoma c e l ls  
(Dautry-Varsat et a l , 1983), in re ticu locy tes (Morgan, 1983b) and in 
erythroleukaemia c e lls  (Klausner et a l , 1983). After release of the 
iron  from the endocytic ves ic le , the vesic le  returns to the ce ll 
surface where i t  fuses with the c e ll membrane. In the process, the
contents of the vesic le  are exposed to physiological pH. At th is  pH,
the apotr ansferr in receptor d is so c ia te s  from the receptor and is  
ava ilab le for further iron transport.
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1 .3 .2 .  R e g u la t io n  o f  ir o n  uptake by e r y t h r o p o ie t ic  c e l l s
The rate of iron uptake by immature erythroid c e lls  is  affected by both 
ex trace llu la r and in tra ce llu la r  factors.
The major ex trace llu la r determinant of iron uptake is  the supply of 
transferrin-bound iron. The rate  of iron uptake by reticu locytes in 
v itro  increases as the concentration of transfe rrin -iron  is  ra ised, 
u n t i l  sa tu ra tion  o f the iron  uptake process occurs. At iron  
concentrations below the saturating leve l, the supply of iron to c e lls  
w i l l  be submaximal and cou ld be the ra te  l im it in g  fa c to r for 
haemoglobin synthesis (Morgan, 1981).
Ce llu la r factors a ffecting  the rate of iron uptake are the degree of 
maturation of c e lls  and the regulatory e ffects of in tra ce llu la r free 
haem. More mature c e lls  show slower rates of uptake of iron. This is 
probably re la ted  to the number of transferrin  receptors on the c e ll.  
With maturation of the erythroid precursors, there is  a decrease in the 
number of transfe rrin  receptors and thus a decrease in the capacity for 
iron uptake by the c e ll (van Bockxmeer and Morgan, 1979).
The concentration of free haem in re ticu locy tes may act as a regulator 
of iron  uptake. The addition of haem to reticu locytes stimulates 
globin synthesis (London et a l , 1964) but in h ib its  haem synthesis and 
iron  uptake by the re ticu locy te  (Ponka and Neuwirt, 1969; 1971).
Inh ib ition  of haem synthesis with ison ico tin ic  acid hydrazide resu lts
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in  increased iron uptake by c e lls ,  while inh ib it ion  of globin synthesis 
reduces iron uptake by c e lls ,  probably as a re su lt  of the accumulation 
of free haem in the c e lls  (Ponka and Neuwirt, 1969; 1971). Haem does
not appear to in h ib it  transfe rrin  uptake by the c e l l ,  but probably acts 
by blocking iron d issociation  from transferrin  (Ponka et a l , 1974).
1.3.3. Erythrocyte ageing
Normal human erythrocytes survive in the c ircu la tion  for about 120 
days. Senescent and damaged erythrocytes are se lective ly  removed from 
the c ircu la t ion  by the reticu loendothe lia l system, in particu lar by 
macrophages in  the spleen and liv e r (Bennett and Kay, 1981). This 
se le c t iv ity  implies that the macrophage can recognize age or damage- 
dependent changes on the surface of the red c e l l .  While considerable 
data ex is t describing the mode of destruction of abnormal red c e lls ,  
re la t iv e ly  l i t t l e  is  known about red c e ll ageing and the mode of 
destruction of senescent red c e lls .  The major obstacle to solving th is 
problem has been the lack of su itable methods for separating young 
c e lls  from old c e lls  (Bunn, 1972). In sp ite of th is a variety of 
changes have been described in  the red c e l l  as i t  ages. Their 
s ign ificance , i f  any, in the fin a l destruction of the ce ll is  unknown.
The uniform ity of the lifespan of the erythrocyte suggests that it s  
destruction is  the re su lt  of age dependent factors. The essential 
steps of erythrocyte senescence occur in the cytosol (Bocci, 1981). In 
the anucleated e ry th rocy te , there is  a progressive dec lin e  of
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metabolism, as evidenced by a f a l l  of ATP concentration (Bunn, 1972). 
ATP depletion is  followed by a progressive increase of in tra ce llu la r 
calcium and i t  has been suggested that th is  increase in calcium may be 
the crucia l event triggering an irreve rs ib le  change in the cytoskeletal 
system of the erythrocyte and a profound red is tr ibu tion  of integral 
membrane proteins (Sheetz and Singer, 1977; Shotton et a l , 1978). The 
changes of the erythrocyte  membrane occurring as a re su lt of the 
cy toso lic  events mentioned may be detected by macrophages and may 
account for the removal of senescent red c e lls  from the c ircu la tion .
The formation of fragments or vesicles as the erythrocyte ages also 
leads to important changes of the erythrocyte membrane which may be 
responsible for removal of senescent red c e lls  from the c ircu la tion . 
Weed and Reed (1966) defined fragmentation as "loss from the ce ll of a 
piece of membrane which may or may not contain haemoglobin". The loss 
of portions of the red c e ll membrane during ageing is  associated with 
an a lte ra tion  of the lip id -p ro te in  ra t io  of the erythrocyte membrane 
and accounts fo r changes in the a c t iv it ie s  of membrane associated 
enzymes found in the erythrocyte (Kadlubowski and Agutter, 1977). Also 
th is  membrane loss may account for decreased membrane f lu id ity  and 
deformabi1ity  (Shiga et a l , 1979). Since the v ia b il ity  of the red ce ll 
in  the c ircu la t io n  is  dependent on it s  a b il it y  to withstand changes in 
it s  shape (Weed, 1970), the decreased membrane deformability consequent 
upon loss of portions of the erythrocyte membrane as i t  ages may be an 
explanation for red c e ll destruction with ageing. In addition, i t  
appears that older red c e lls  are smaller than younger ones and they
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have an increased density (Ganzoni et a l , 1971). This may be another 
reason why older red c e lls  are more r ig id  and less able to withstand 
changes in the ir shape.
I t  has been reported that older red c e lls  contain less s ia l ic  acid than 
do young red c e lls  (Aminoff et a l , 1980; Bocci, 1981). Red ce lls  
depleted o f s i a l i c  a c id  enzym atica lly  have been found to have a 
shortened survival (Durocher et a l , 1975). I t  was thus suggested that 
the decrease in s ia l ic  acid content of older red c e lls  may be a factor 
responsible for erythrocyte destruction. However th is  has been a 
c o n t r o v e r s ia l  is su e  w ith  d ivergen t re s u lt s  being obtained in  
experiments involving a r t i f i c ia l  desialyation of red c e lls .  The reason 
fo r th is  may be that senescence of red c e lls  induces changes more 
complex than those obtained by a r t i f i c ia l  desialyation of red c e lls  and 
the re fo re  the p h y s io lo g ica l meaning of those resu lts  is  doubtful 
(Bocci, 1981). The facts of the matter are that during ageing loss of 
carbohydrate with portions of the red c e ll membrane are occurring. 
Th is may r e s u lt  in  a decreased s i a l i c  a c id  co n ten t o f o ld e r 
e ry th ro c y te s ,  but the s u r fa ce -ch a rg e  d e n s ity  and hence the 
e le c tro p h o re t ic  m o b ility  o f the e ry th rocyte  remains unchanged 
throughout the whole lifespan of the erythrocyte (Luner et a l , 1977; 
Seaman et a l , 1977).
Though the loss of s ia l ic  acid residues from the membranes of mature 
red c e lls  may not a lte r the surface charge density of the c e l l ,  the 
cleavage o f these s ia l ic  acid residues may mediate the removal of
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senescent red c e lls  from the c ircu la tion  by another mechanism. I t  has 
been suggested  th a t  younger re d  c e l l s  exp ress  te rm ina l N- 
acetylneuraminic acid residues on the glycoproteins of their surface 
membranes, whereas older red c e lls  appear to lack such s ia l ic  acid 
residues on the ir glycoproteins (Alderman et a l , 1981). The loss of 
the terminal s ia ly l residues may reveal Ig-binding s ite s  on these 
desialyated glycoproteins. Antibodies, for example IgG, are directed 
against these binding s ite s  (Kay, 1975). The antibody-coated senescent 
red c e lls  are then opsonized and subjected to phagocytic removal by 
re ticu loendo the lia l macrophages. I t  may be tha t the an tibod ies 
accumulate on the red c e ll surface as the c e ll ages and that upon 
reaching a c r it ic a l concentration, the red c e ll may be su ff ic ie n t ly  
coated w ith  an tibod ies  to be recognised by the macrophage and be 
phagocytosed (Kay, 1975). In addition macrophages are well documented 
as e x h ib it in g  an a s ia lo g ly co p ro te in  recepto r on th e ir  surfaces 
(Hamilton et a l , 1984).
Advanced glycosylation endproducts (AGE) on erythrocyte c e ll surfaces 
have recently been shown to promote the clearance of aged erythrocytes 
(Vlassara et a l,  1987). The advanced glycosylation endproducts, formed 
as a re su lt  of the nonenzymatic reaction of glucose with amino groups 
of proteins (including haemoglobin), accumulate in ex trace llu la r and 
membrane proteins as a function of time and glucose concentration  
(Brownlee e t a l , 1984). A recently id en tified  membrane-associated 
macrophage receptor that recognizes proteins modified by th is  process 
of long term nonenzymatic AGE formation has been implicated in the
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preferentia l removal of senescent macromolecules (Vlassara et a l , 1984; 
1985) and may also mediate the endocytosis o f e ry th rocy tes w ith 
advanced glycosylation endproducts formed on the ir surface (Vlassara et 
a l,  1987).
The loss of membrane l ip id  during the lifespan of mature red c e lls  has 
also received attention as a possible cause for the destruction of 
senescent red c e lls .  Reticulocytes are r ich  in membrane lip id s  and 
th is  excess l ip id ,  present both in  in tra ce llu la r organelles and plasma 
membranes is  lo s t  during re ticu locy te  maturation (Shattil and Cooper, 
1972).
Recently a new technique has been developed in  an attempt to identify  
the basis for se lective elim ination of senescent red blood c e lls  by 
macrophages. Th is technique involves the use of IC-21 c e lls ,  an 
established line  of Simian v iru s  40-transformed mouse peritonea l 
macrophages (Walker et a l,  1984). These macrophages bind and ingest 
populations of homologous red c e lls  that are aged in vivo by seria l 
hyper transfusion. I t  is  hoped that by a lte ring  the aged red ce lls  in 
various ways, the IC-21 macrophage lin e , used with the in vivo aged 
erythrocytes, w ill a fford  a model system for iden tify ing  more precisely 
the mechanisms of macrophage mediated phagocytosis of senescent red 
c e lls  (Walker et a l , 1984).
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1.4 THE RETICULOENDOTHELIAL SYSTEM (RES)
1.4.1. Introduction
The RES is  made up of the scattered and h is to lo g ica lly  heterogeneous 
c e lls  in the body which have in common the property of phagocytosis. 
There are three main components of the RES. They are the reticulum 
c e lls  which produce re t ic u lin  fib re s , the phagocytic endothelial c e lls  
lin in g  the blood ca p illa r ie s  of the liv e r ,  splenic sinusoids, lymph 
nodes, bone marrow, adrenal and p itu ita ry  glands and the macrophages of 
tissues, also known as h is tio cy tes, and of blood, known as monocytes. 
After leaving the bone marrow, mononuclear phagocytes travel through 
the blood as monocytes before reaching those target tissues where they 
constitute the re s id e n t macrophage popu la tion . Resident t issu e  
macrophages or h is t io c y te s  e x is t  in  protean forms, including the 
hepatic kupffer c e l l ,  alveolar macrophage of the lung, giant ce ll of 
granulomas, dermal Langerhans c e l l ,  m icrog lia l c e ll of granulomas, 
peritonea l and p leu ra l macrophage and probably the os teoc la st 
(Abramson et a l , 1977; C line et a l , 1978). Although macrophages, 
endothelial c e lls  and fib rob lasts  are anatomically associated in the 
RES, these c e ll types are not developmentally re lated. Macrophages are 
derived from marrow haemopoietic progenitors, whereas endothelial c e lls  
and f ib ro b la s ts  are somatic c e l ls  derived from the entoderm and 
mesenchyme respective ly.
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The RES plays an important ro le  in the internal iron economy of the 
body. This function is  effected by the uptake and catabolism of effete 
and senescent red c e lls ,  the removal of iron from the haemoglobin and 
the return of th is  iron to the plasma where i t  is  bound by transferrin  
and transported to the bone marrow (Lynch et a l , 1974). In the bone 
marrow, the iron is  u t i l is e d  in haemoglobin synthesis. In addition to 
being the main source of iron entering the plasma, the RES is  also 
concerned with the storage of iron which is  not immediately required 
fo r the synthesis of m etabolically active compounds. Under normal 
circumstances, the reticu loendothe lia l c e lls  of the spleen, live r and 
bone marrow are those most concerned with iron metabolism.
The fo llow ing section w ill deal with 3 aspects of reticu loendothe lia l- 
iron in teractions, namely iron entry into re ticu loendothe lia l c e lls ,  
haemoglobin degradation and iron metabolism in  re t ic u lo e n d o th e lia l 
c e lls .
1.4.2. Iron entry into reticu loendothe lia l (RE) c e lls
The RES derives most of it s  iron d ire c tly  from catabolised haemoglobin. 
Two-thirds of th is  iron comes from red blood c e lls  sequestered by the 
RES at the end of the ir lifespan. The remainder is  derived from 
haem oglobin re le a s e d  as a r e s u lt  o f c e l lu la r  wastage during 
erythropoiesis and from non-haem iron that has been removed from viable 
erythrocytes (Cook et a l , 1970).
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Extrace llu la r haemoglobin present in plasma does not reach the RES. I t  
is  largely bound to haptoglobin and haemopexin and is  removed from the 
c irc u la t io n  by hepatocytes (see section 1.5.3.1.) or by the kidney 
(Noyes et a l , 1960). Small quantities of fe r r it in  w ithin erythrocytes 
transferred d ire c t ly  to RE c e lls  also provide source of iron for the 
RES (Deiss and Cartwright, 1970).
Another source o f iron  entering the RE ce ll is  transferrin  iron. 
Transferrin receptors have been found on human macrophages and i t  has 
been shown that transferrin  iron is  taken up by these c e lls .
1.4.2.1. Phagocytosis of aged, abnormal or damaged erythrocytes
Senescent, damaged and abnormal red blood c e lls  are se lective ly  removed 
from the c ircu la t io n  and catabolised by c e lls  of the RES, in particu lar 
by macrophages in the spleen, liv e r and to a lesser extent by c e lls  in 
the bone marrow (Bennett and Kay, 1981). The most commonly used method 
of the study of the s ite s  of phagocytosis of red c e lls  involves the 
infusion of damaged red c e lls ,  usually labe lled  with rad io iron . This 
is  followed either by surface counting or by d ir e c t  counting of 
extripated organs to iden tify  s ites  of concentration of the isotope 
(Deiss, 1983). Several modes of c e ll damage have been used, including 
ageing, heat damaging and chemical and immune injury to the c e ll.  As 
discussed previously, the actual a lterations in senescent red ce lls  
tha t determine the end of the ir lifespan have not yet been fu lly  
e lu c ida ted  (sec tion  1 .3 .3 .) .  While the phagocytic function  of
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mononuclear phagocytes is  genera lly  acknowledged, the mechanisms 
resposib le for the ingestion of aged erythrocytes remain a matter of 
debate.
Most of the phagocytosis of senescent red c e lls  occurs in the sinusoids 
of the liv e r and spleen which are large capacitance systems. Thus the 
slow passage of blood through these sinusoids, combined with the 
presence of large numbers o f phagocytes w ith extended d e n d r it ic  
processes provides favourable conditions for macrophages to recognise 
and phagocytose c e lls  (Kay, 1975).
The contact between the erythrocyte and the macrophage induces the 
subsequent events. A small area on the surface of the erythrocyte 
in i t ia l ly  attaches to the macrophage. This is  followed by sphering of 
the red c e ll and it s  envelopment by a hyaloplasmic v e il from the 
phagocyte (Lynch e t a l,  1974). A fte r the d is integration of the 
erythrocyte, the haemoglobin is  in i t ia l ly  located mainly in endocytic 
vacuoles known as phagosomes. These then merge with primary lysosomes 
which supply ly t ic  enzymes capable of degrading haemoglobin (Lynch et 
a l, 1974).
1.4.2.2. Transferrin receptor a c t iv ity  on macrophages
I n it ia l ly  i t  was believed that iron entered the RES exclusively by the 
phagocytosis of red c e lls  and the ir waste products. However, i t  became 
clear that RE c e lls  could also take up transferrin-bound iron in v itro .
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Macsween and coworkers (1969) were the f i r s t  to demonstrate that 
pulmonary and peritoneal macrophages and Kupffer c e l ls  a ss im ila ted  
transferrin-bound iron from a prepared medium. These findings are in 
keeping with subsequent observations of the p rog ress ive  uptake of 
transfe rrin  by cultured macrophages (Summers and Jacobs, 1976; Wyllie, 
1977; Sizemore and Bassett, 1984; Baynes et a l , 1987c).
Macrophages appear to be heterogeneous in  th e ir  expression o f 
transfe rrin  receptors. Human monocytes and resident and a c tiva ted  
macrophages have absent or diminished transferrin  receptor expression. 
Transferrin receptor expression appears to be enhanced on responsive 
macrophages and cultured macrophages (Ancfr*eesen et al 1983; Parmley et 
a l , 1983; Hamilton et a l , 1984). The resident tissue macrophage 
represents a quiescent c e ll in  that i t  does not respond to lymphokine 
or endotoxin by becoming cy to ly t ic  . A responsive macrophage is  one 
that becomes cy to ly t ic  when exposed to endotoxin after prior lymphokine 
stim ulation. An activated macrophage is  fu l ly  cy to ly t ic .
Until recently iron uptake by cultured macrophages has been assumed to 
be by receptor-mediated endocytosis. There was however l i t t l e  d irect 
evidence for th is . A recent study by Baynes and colleagues (1987c) 
confirmed the existence of d i f f e r ic  t ra n s fe r r in  recepto rs on the 
surface of cultured human blood monocytes and demonstrated the receptor 
mediated uptake of transfe rrin  iron by cultured macrophages. Th is 
uptake was shown to be by an endocytic pathway very sim ilar to that 
noted in erythroid precursors.
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The reason for the existence of such a pathway in RE c e lls  is  unclear, 
since these c e lls  acquire large amounts of iron from the haemoglobin of 
e ffe te  and senescent c e lls .  I t  may be that the interaction  between 
transfe rrin  iron and macrophages p lays a r o le  in  re g u la t in g  the 
d iffe ren tia t io n  and p ro life ra t ion  of resident macrophages (Andreesen et 
a l , 1983; Galbraith et a l , 1980; May et a l , 1985).
1.4.3. Haemoglobin degradation
Fo llow ing  phagocytosis and red  c e l l  ly s is ,  haemoglobin (Fe2+) is  
converted in to  methaemoglobin (Fe2+). After globin is  s p l it  from
methaemoglobin i t  is  hydrolysed to it s  constituent amino acids, which 
mix with the general amino acid pool (Ehrenreich and Cohn, 1968). Iron 
is  re leased from the haem (Fe2+) by the action of microsomal haem 
oxygenase (Tenhunen, 1972). Th is enzyme is  demonstratable in 
peritoneal macrophages, blood monocytes, Kupffer c e lls ,  macrophages of 
the bone marrow and lung, in  b ra in  g l ia l  c e l l s ,  as w ell as in  
hepatocytes and renal tubular ep ith e lia l c e lls .  A c t iv ity  of haem 
oxygenase is  highest in the spleen, followed by the bone marrow and 
then the liv e r (Tenhunen et a l , 1970). A c t iv ity  in a l l  these c e lls  may 
be induced by exposing them to haem compounds.
Microsomal haem oxygenase u t i l is e s  molecular oxygen and NADPH in it s  
degradation of haem. The NADPH is  generated through an NADPH dependent 
cytochrome c reductase (Elder, 1980). Haem oxygenase disrupts the 
alpha carbon bridge of the te trapyrro lic  haem molecule. For every
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m olecule o f haem thus degraded one molecule of bi liv e r din and one 
molecule of carbon monoxide re su lt. The bi l iv e r  din is  promptly 
converted to b iliru b in  by a second enzyme, b iliv e rd in  reductase, which 
is  present in  the so lu b le  f r a c t io n  of the same c e l ls  in  which 
b iliv e rd in  is  formed from haem (Tenhunen, 1972).
1.4.4. Iron metabolism in the RE ce ll
Once iron is  freed from haemoglobin, i t  may either return to the plasma 
or become incorporated in iron stores. The proportion fo llow ing each 
route is  influenced by various factors. The incorporation of iron into 
iron stores is  covered in  section 1.6. and the factors influencing iron 
release from c e lls  is  discussed in section 1.7.
In it ia l studies showed that after the release of iron from haem, part 
of the red c e ll iron processed by the RE ce ll is  rap id ly  returned to 
the plasma, and another portion exchanges with RE stores and is  slowly 
re u t il is e d  (Noyes et a l , 1960; L ipsch itz et a l , 1971c). This gave 
r is e  to the concept of the early release pool, also known as the "pre­
re lease” pool or the la b ile  iron pool, and a slow storage pool. The 
k in e t ic s  o f these pools were further characterized by F i l l e t  and 
coworkers (1974), who showed tha t in  dogs there was an i n i t i a l  
processing  period  w ith in  the RE c e l l  o f ra d io iro n  derived from 
labe lled , heat damaged red c e lls .  After th is  the rad io iron was either 
ra p id ly  retu rned  to the c ir c u la t io n  (t*/2 = 34 minutes) or was 
transferred to a slowly exchanging pool of storage iron w ithin the RE
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ce ll ( t i/2  release to plasma of 7 days). These pathways were of equal 
magnitude in the normal dog.
While the presence of an intermediate " la b ile  iron pool" had been 
postulated, i t  is  on ly re c e n t ly  tha t th is  pool has been better 
characterized. This la b ile  iron pool or low molecular weight iron pool 
as i t  is  now known is  dealt with in section 1.8.
The passage o f iro n  through the RE c e l l  can be summarized 
diagramatically (figure 1; May and W illiams, 1980). The input flux 
re fe rs  to iron  en te ring  the c e l l  as a r e s u lt  o f catabolism  of 
haemoglobin from e ffe te  or senescent red c e lls .  This iron enters the 
rap id ly  exchangeable iron pool which is  made up of low molecular weight 
and la b ile  protein- or polypeptide-bound iron. Most of the "chelatable 
iron" in ce ll cytoplasm is  derived from th is  rap id ly  exchangeable iron 
pool. The slowly exchangeable iron pool represents fe r r it in .  Iron may 
also be taken up by the c e ll from transfe rrin , or may be donated to 
transfe rrin .
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Figure 1. Schematic diagram of the passage of iron through the RE 
c e l l .
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1.5 HEPATOCYTE IRON UPTAKE
1.5.1. Introduction
V irtu a lly  a l l aspects of iron metabolism are represented in  the liv e r . 
The liv e r is  the p rinc ipa l organ of iron storage in fe r r it in  (Kondo et 
a l , 1988 ) .  I t  c o n t a in s  two m ajor c e l l  t y p e s ,  nam ely
v reticu loendothe lia l c e l ls ,  also known as Kupffer c e lls ,  and parenchymal 
c e l ls  or hepatocytes. The Kupffer c e l l ,  l ik e  other c e lls  of the 
reticu loendothe lia l system, is  capable of processing and re leasing iron 
acquired by phagocytosis of red blood c e lls ,  and is  a major s ite  for 
restoring iron from senescent erythrocytes to the c ircu la tion  (Kondo et 
a l,  1988).
The hepatic parenchymal c e ll is  second only to the erythroid bone 
marrow in it s  capacity for iron exchange w ith  plasma t ra n s fe r r in  
(Morgan and Baker, 1986). Hepatocytes take up transfe rrin  iron, haem- 
haemopexin iro n , haptoglobin-haem oglobin iron  and f e r r i t in  iron  
(Hershko et a l , 1972). Another transferrin  iron uptake pathway has 
been described which involves the interaction  of desialated transferrin  
with non-specific asia loprote in  receptors on hepatocyte surfaces (Young 
et a l,  1983; Dekker et a l , 1985; Tavassoli et a l , 1986; Rudolph and 
Regoeczi, 1988). Recently attention has focused on hepatic clearance 
of the small pool of low molecular weight iron complexes (Wright et a l , 
1988).
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The fo llow ing section w il l  deal with the various routes u t iliz e d  by 
hepatocytes in the ir acqu is ition  of iron.
1.5.2. Uptake of transferrin-bound and asialotransferrin-bound iron
Plasma transfe rrin  is  thought to be the most s ig n ific an t source of iron 
for the hepatocyte, with some 10-20% of plasma iron turnover in rats 
being directed at the hepatocyte (Page et a l , 1984). A number of 
mechanisms are responsible for hepatocyte iron uptake from transferrin . 
These include a combination of receptor mediated endocytosis, which is  
most e ffe c tive  at lower transfe rrin  concentrations, and non-saturable 
transfe rrin  binding which occurs mainly at higher concentrations of 
t r a n s fe r r in  (Page e t a l ,  1984; Trinder e t a l , 1986). Since 
transfe rrin  iron uptake by hepatocytes is  in h ib ite d  by the energy 
metabolism blocking agent cyanide (Thorstensen and Romslo, 1986), a 
large part of th is  uptake must involve energy dependent processes.
Recent work has indicated that when compared to erythroid precursors 
hepatocytes have much higher concen tra tions o f surface membrane 
ferro-reductase a c t iv ity . This observation may suggest that in the case 
of hepatocytes, after d ife r r ic  transferrin  has bound to the surface 
receptor, the iron may be liberated at the c e ll surface and reduced to 
the ferrous state whereafter transmembrane transport of th is  iron can 
occur (Thorstensen, 1988). After transferrin -iron  is  taken up by 
normal cu ltu red  hepatocytes, approx im ate ly  tw o - th ird s  o f the 
endocytosed iron accumulates in fe r r it in  (Trinder et a l , 1986).
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The mechanism whereby a s ia lo t r a n s fe r r in  d e liv e rs  i t s  iron  to 
hepatocytes is  complex and incom plete ly  understood. There is  
disagreement as to whether the asia l otransferr in is  taken into the 
hepatocyte via the conventional d i f e r r ic  t ra n s fe r r in  receptor or 
whether i t  enters the hepatocyte via an asia loprotein  receptor (Young 
et a l , 1983; Dekker et a l , 1985; Rudolph and Regoeczi, 1988). The 
hepatocyte appears to have an asia loprotein  receptor known as the 
asialoglycoprotein-binding le c t in  which seems to be concerned with the 
removal o f d e s ia la ted  p ro te in s  from the c ircu la tion  (Ashwell and 
Harford, 1982). Tavassoli and coworkers (1986) showed tha t hepatic 
endothelium possesses the a b il it y  to transport endocytosed transferrin  
from the vascular lumen to the hepatocyte side of the endothelium. In 
the process the transfe rrin  was desialated and was subsequently taken 
up by hepatic asia loprote in  receptors. Young and coworkers (1983) 
suggested tha t a s ia lo t r a n s fe r r in  can be endocytosed by suspended 
hepatocytes via either the transferrin  receptor or the asialoprotein 
receptor. They concluded that the net uptake of as ia lo transferrin  was 
the sum of both pathways. Another group of investigators (Dekker et 
a l , 1985) proposed that iron uptake from ra t  as ia lo transfe rrin  occurs 
via transfe rrin  receptors, and that when taken up by the asialoprotein 
receptor, the transfe rrin  is  recycled without unloading it s  iron. More 
re c e n t ly  i t  has been proposed tha t the a s ia lo p ro te in  receptor 
fa c i l it a te s  capture of the as ia lo transfe rrin  by the same binding sites 
that are normally ava ilab le  fo r t ra n s fe r r in  ra ther than tha t i t  
functions as an alternate pathway (Rudolph and Regoeczi, 1988).
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1 .5 .3 .  Uptake o f  n o n - tra n s fe r r in -b o u n d  ir o n
Under normal circumstances, non-transferrin-bound iron represents only 
a minor source of hepatocyte iron when compared with transferrin , but 
the quantitative s ign ificance  of th is  form of iron increases in various 
settings.
1.5.3.1. Haptoglobin and haemopexin
Haemoglobin in troduced  in to  the plasma fo llo w in g  in travascu la r 
haemolysis binds to haptoglobin, or to haemopexin i f  the haptoglobin 
binding capacity of the plasma is  exceeded as occurs when intravascular 
haemolysis increases greatly in haemolytic diseases and those disorders 
associated with high leve ls of in e ffe c tive  erythropoiesis (Morgan and 
Baker, 1986). Both haptoglobin-haem oglobin and haem-haemopexin 
complexes are taken up by hepatocytes (Hershko et a l , 1972). This 
uptake process appears to be by receptor mediated endocytosis, with the 
process showing several s im ila r it ie s  to that of transfe rrin -iron  uptake 
(Smith and Morgan, 1981). Within the hepatocyte, these complexes are 
catabolized and iron is  released from the porphyrin ring  of haem by 
haem oxygenase. The iron then enters an in tra ce llu la r  pool common to 
that derived from transferrin  and fe r r it in  (Morgan and Baker, 1986). 
Haem bound to albumin as methaemalbumin is  also taken up by hepatocytes 
but without binding of the albumin to the c e lls .  I t  is  l ik e ly  that the 
uptake mechanism involves transfer of the haem to haemopexin, which is
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then taken up by the hepatocyte in the usual fashion (Morgan and Baker,
1986).
1.5.3.2. Serum fe r r it in
As is  discussed in  section 1.6.3. small quantities of fe r r it in  are 
present in  plasma under normal conditions, and higher amounts are 
present in plasma when iron stores are increased. I t  has been shown 
that fe r r it in  introduced in to  the plasma is  rap id ly  cleared from the 
c ircu la t ion  by hepatocytes. This is  a receptor-mediated process (Mack 
et a l,  1983; Morgan and Baker, 1986) and probably involves endocytosis 
fo llow ed  by fu s ion  o f the endocytic v e s ic le s  with lysosomes and 
degradation of the protein (Unger and Hershko, 1984). Plasma fe r r it in  
w ith  a high iron  content, as occurs under cond itions of tissue 
necrosis, has to be considered as a potential source of iron uptake by 
the liv e r (Bacon and T a v ill,  1984). Also, in pathological conditions 
in which iron stores are elevated, plasma fe r r it in  probably represents 
an important source of hepatocyte iron and contributes to parenchymal 
iron overload (Morgan and Baker, 1986).
Recent experim en ts suggest th a t  in  ad d it io n  to i t s  ro le  in  
in tra ce llu la r iron storage, fe r r it in  may also serve as an intrahepatic 
carrie r of iron between Kupffer c e lls  and hepatocytes (Kondo et a l , 
1988; S ib i l le  et a l , 1988). The av id ity  with which hepatocytes take 
up fe r r it in  released from Kupffer c e lls  may explain the su scep tib ility  
of the liv e r to iron overload (S ib il le  et a l , 1988).
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In contrast to the conservation of transferrin  during it s  interaction 
with hepatocytes, the protein shell of the fe r r it in  molecule is  rap id ly  
degraded in to  tr ich lo ra ce t ic  acid-soluble fragments (S ib ille  et a l , 
1988).
1.5.3.3. Low molecular weight iron complexes
Although most of the iron in  plasma is  bound to transfe rrin , there is  
increasing evidence that low molecular weight iron complexes present in 
plasma are an important source of iron for the ra t live r (Brissot et 
a l , 1985; Wright et a l , 1986). The plasma concentration of th is  form 
of iron, which is  thought to consist of a mixture of iron complexes 
with ascorbate, carbonate, certa in  amino acids and to a lesser extent 
plasma p ro te in s  such as album in, is  extremely small in  normal 
ind iv idua ls . However much higher concentrations have been reported in 
iron overload when the sp ec ific  iron binding s ites  of transferrin  are 
saturated and iron added to the plasma cannot bind to transferrin  (see 
section 1 .2.3.3.).
Hepatic clearance of low molecular weight plasma iron complexes appears 
to be an extremely e f f ic ie n t  process, with 58-75% removed in a single 
pass through the liv e r  (Brissot et a l , 1985). Autoradiography has 
confirmed that most iron  removed in  th is  process is  c lea red  by 
parenchymal c e lls  (Brissot et a l,  1985).
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Unlike uptake of transferrin, hepatic uptake of these low molecular 
weight iron complexes is not reduced by iron loading (Wright et a l , 
1986). In addition, this transport mechanism appears to be carrier- 
mediated as evidenced by saturation, competitive inhib ition by other 
transition metal ions and temperature dependence. Iron uptake by this 
mechanism is  a lso strongly calcium dependent and is  re la t iv e ly  
insensitive to inhib itors of ce llu lar energy metabolism (Wright et a l , 
1986).
The very high effic iency of hepatic uptake of this form of iron far 
exceeds the rate of transport of physiologic ions in serum (Wright et 
a l, 1988). The basis for this high effic iency is largely unknown. 
Recent data has confirmed that hepatic uptake of these low molecular 
weight iron complexes is mediated by a membrane carrier in the rat 
liver and strongly suggests that uptake occurs by an electrogenic 
transport mechanism that is driven by the potential difference across 
the liver ce ll membrane (Wright et a l , 1988). Hepatic accumulation of 
other transition metal ions such as copper, zinc, and manganese may be 
driven by similar forces since there is evidence that these ions share 




Iron tha t is  not immediately needed to mediate one of it s  many 
b io log ica l functions in c e lls  and that is  present in excess quantities 
in  the ce ll is  diverted into iron stores. This surplus iron is  stored 
in one of two re la ted  forms, namely a soluble mobile fraction  known as 
fe r r it in ,  or as insoluble aggregates known as haemosiderin (Worwood, 
1982). The ro le  of fe r r it in  in d iffe ren t c e ll types includes both 
sp e c ia liz e d  fu n c tion s  and in t ra c e l 1 u la r housekeeping functions. 
Examples o f s p e c ia liz e d  fun c tion s  are the re c y c lin g  o f iron  in  
macrophages and short and long term iron storage as in red c e lls  of
embryos or hepatocytes of adults. In trace llu la r housekeeping functions
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in c lude  p rov id ing  a reserve of iron for cytochromes, nitrogenase, 
ribonucleotide reductase, and for detox ifica tion  of excess iron that 
may enter the c e ll (The il, 1987). Recently i t  has been suggested that 
fe r r it in  may serve as an intrahepatic carrier of iron between Kupffer 
c e l ls  and hepatocytes (Kondo et a l , 1988: S ib i l le  et a l , 1988).
Although the iron in haemosiderin is  not as immediately accessible to 
the ce ll as is  the iron from fe r r it in ,  i t  is  read ily  mobilisable in the 
face of increased body needs (Bothwell et a l , 1979; Halliday and
Powell, 1984). Iron stored as fe r r it in  in  the parenchymal c e lls  of the 
liv e r accounts for approximately a th ird  of the tota l storage iron 
(Powell and Halliday, 1982). The remainder of the body's reserve iron 
is  stored as haemosiderin w ithin the c e lls  of the reticu loendothe lia l
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system in the l iv e r ,  spleen, bone marrow and skeletal muscle (Bothwell 
et a l , 1979; Powell and Halliday, 1982).
1.6.2. F e r r it in
1.6.2.1. Structure
The f e r r i t i n  m olecule comprises a g lobu la r prote in  shell ca lled 
apo fe rr it in , with a central cav ity  w ith in  which iron  accumulates 
(H a rr is o n ,1980). A p o fe r r it in  is  a co lo u r le ss  molecule, whereas 
fe r r it in  has a deep red-brown colour when i t  carries a fu l l  compliment 
of iron (Bothwell et a l , 1979; Worwood, 1980). Apo ferritin  has a 
molecular weight of between 450-480000 dal ton, is  water soluble and 
re la t iv e ly  heat stable (Harrison et a l , 1980). I t  is  composed of 24 
polypeptides or subunits arranged in  a symmetrical fashion to form the 
ho llow , almost sphe rica l shell (Harrison, 1980). Hydrophobic and 
hydrophilic channels ex is t between the subunits. Small m olecules, 
in c lu d in g  iron  and sucrose enter in to  the central cavity of the 
molecule through these channels (Crichton and Charloteaux-Wauters,
1987). Up to 4500 iron atoms can be included in  the core along with 
variable amounts of phosphate (Mann et a l , 1986).
F e r r i t in  is  not a homogeneous protein, but consists of up to 20 
is o fe r r it in s  (Bomford and Munro, 1980). The evidence for th is  has been 
the find ing that fe r r it in  from d iffe ren t organs isofocuses over a pH 
range of 4.8 to 5.8 and gives several bands of is o fe r r it in s  (Drysdale
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e t a l , 1977 ; A ro s io  e t a l , 1978). On sodium sulphate or 
polyacrylamide gel e le c tro p h o re s is , two major subunit bands are 
evident. I t  is  variations in the proportions of these two subunits, 
which d iffe r  in s ize , amino acid com position, surface charge and 
im m unoreactivity tha t g ive r i s e  to the heterogeneity of fe r r it in  
(Drysdale, 1977). The two subunits are designated H and L respectively 
and have molecular weights of 21000 and 19000 (Arosio et a l , 1978). 
The range of is o fe r r it in s  found varies from tissue to tissue (Worwood, 
1980). Iso fe rr it in s  from the heart, lymphocytes and red blood ce lls  
consist mainly of H subunits and are re la t iv e ly  ac id ic  in nature, while 
is o fe r r it in s  from the liv e r ,  spleen and placenta consist mainly of L 
subunits and are more basic (Worwood, 1986). The ac id ic  H subunits 
appear to contain a higher proportion of iron r ich  molecules (Treffrey 
et a l , 1984). The H and L subunits are synthesized as independent
polypeptide chains (Watanabe and Drysdale, 1981). While i t  has been
discovered that the H and L subunits are coded fo r by genes on 
chromosomes 11 and 19 respective ly (Worwood et a l,  1985), H and L 
sequences have also been found on other chromosomes (Cragg et a l , 1985; 
M cg ill et a l , 1987).
1.6.2.2. Synthesis
The stim uli for fe r r it in  synthesis are decreasing leve ls of fe r r it in  in 
the c e ll and excess iron that enters the c e ll (Finch et a l , 1986). For
fe r r it in  to f u l f i l  i t s  ro le  of storing excess iron, there must be a
mechanism whereby the excess iron can be rap id ly  incorporated into
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fe r r it in  so as to protect the c e ll from tox ic leve ls of iron. While 
some of the iron is  incorporated into pre-existing apo fe rrit in , the 
high leve ls of in tra ce llu la r iron induce fe r r it in  synthesis in a unique 
fashion (Bomford and Munro, 1980).
There ex ists a cytoplasmic store of fe r r it in  L and H subunit mRNA. In 
response to increased in tra ce llu la r leve ls of chelatable iron, there is  
movement o f t h is  f e r r i t i n  mRNA from r ib o n u c le o p ro te in s  to 
polyribosomes, with resu lt ing  increased fe r r it in  mRNA translation  (Aziz 
and Munro, 1986; Hentze et a l , 1987; Rogers and Munro, 1987; Casey 
et a l , 1988; Dickey et a l , 1988; Leibold and Munro, 1988). Recent 
s tud ies  have shown tha t the tra n s la t io n a l regulation of fe r r it in  
synthesis in storage c e lls  is  achieved by the interaction  of iron with 
a so lu b le  p ro te in  mediator that is  attached to the fe r r it in  mRNA 
(Leibold and Munro, 1988). The area to which the protein mediator is  
attached is  c a lle d  the iron  responsive element. I t  is  a highly 
conserved stem loop structure on the 5 '-untranslated region of the 
fe r r it in  mRNA and as a re su lt  of the attachment of iron to the protein 
mediator, the mediator is  removed from the iron responsive element 
(Hentze et a l,  1987; Aziz and Munro, 1987). The unmasked region that 
resu lts  then in teracts with a high a f f in ity  s ite  on the polyribosome 
and translation  of the mRNA occurs. Recent evidence would seem to 
ind icate that enhanced transcrip tion  may also play a minor ro le  in the 
indu ction  o f f e r r i t in  subunit synthesis by iron (White and Munro,
1988).
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However, because fe r r it in  functions both as a housekeeping protein 
(iron stored for in tra ce llu la r use) and a spec ia lized -ce ll p ro te in  
( iron  stored  for use by other c e lls ) ,  mechanisms of regulation of 
fe r r it in  synthesis may vary depending on the c e ll type (The il, 1987). 
In contrast to storage c e lls  which contain abundant fe r r it in  mRNA that 
iron re c ru its  for transla tion , in non-specialized c e l ls  which only 
require fe r r it in  for metabolic needs, the concentration of fe r r it in  
mRNA is  low and increased in tra ce llu la r  iron induces a change in the 
mRNA concen tra tion  by enhancing transcrip tion  or by a lte ring  mRNA 
s ta b il ity  (Cairo et a l , 1985; Dickey et a l , 1987).
1.6.2.3. Iron incorporation and release
The exact mechanism whereby iron is  incorporated in to  and released from 
a p o fe r r it in  in  vivo has not been elucidated (Hal 1 iday and Powell, 
1984). Iron is  taken up in to  the a p o fe r r it in  sh e ll through i t s  
structural channels (Harrison et a l, 1980). In v itro  studies have 
shown that th is  iron is  in  the ferrous form and tha t i t  is  then 
oxidized to fe r r ic  iron (Bothwell et a l , 1979). The apo fe rritin  shell 
catalyses th is  reaction  in  which molecular oxygen functions as the 
electron acceptor (Bomford and Munro, 1980). Following hydrolysis the 
iron is  deposited in the in te r io r of the apo fe rrit in  shell in the form 
of inorganic hydrated fe r r ic  oxide phosphate m icelles (Harrison et a l , 
1980). These m icelles form a nucleation centre upon which further 
m icellar growth takes place, the amount of iron taken up by fe r r it in  
being determined by the ava ila b le  surface area o f the iron  core
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(Harrison et a l,  1980). This has been confirmed by k ine tic  studies 
which have shown th a t iro n  uptake by a p o f e r r i t in  in c re a se s  
progressively un til a 25% saturation level is  approached after which 
time iron uptake decreases (Harrison et a l , 1980).
Iron contained in  fe r r it in  is  read ily  availab le for use in functional 
iron compounds when required (Bothwell et a l , 1979). Iron release from 
the iron core occurs such that the iron atoms are stripped o ff the iron 
core layer by layer, with the iron atoms on the outermost layer being 
the most ava ilab le for release (Harrison et a l,  1980). Studies where 
rad io iron  incorporated onto fe r r it in  la s t  is  the f i r s t  to be released 
have confirmed th is  " la s t- in - f irs t-o u t"  concept of iron mobilization 
from fe r r it in  (Hoy et a l , 1974).
Iron release from fe r r it in  may occur by reduction of fe r r ic  iron to 
ferrous iron in  the presence of the appropriate chelator, or i t  may 
occur by d irect chelation of fe r r ic  iron (Crichton and Charloteaux- 
Wauters, 1987). In v itro  studies have shown that fe r r it in  iron release 
by reduction of fe r r ic  iron to the ferrous forms occurs more rap id ly  
than does the d ir e c t  ch e la t io n  o f f e r r i c  iro n  (C r ich to n  and 
Charloteaux-W auters, 1987). Reduced fla v in  nucleotides have been 
implicated as the chelators which may mediate the fe r r ic - fe r ro u s  
reduction of iron (Harrison et a l , 1980). I t  is  thought that the 
reduced fla v in s , with the ir small diameters of 1.3 nm, are capable of 
traversing the channels of the apo fe rrit in  shell and reacting with the 
iron contained w ithin the c ry s ta llin e  la t t ic e  (Hoy et a l , 1974).
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However doubt has been cast on the ro le  played by reduced flav ins in 
iron  re le a se  from f e r r i t i n  by the f in d in g  th a t  in  v iv o  the 
in tra ce llu la r  concentration of free flav in s  is  very low (Crichton and 
Charloteaux-Wauters, 1987).
1.6.2.4. F e r r it in  catabolism; haemosiderin
Apo ferritin  has a f in it e  lifespan and must constan tly  be renewed 
(Bothwell et a l , 1979). When laden with iron, the protein has a ha lf 
l i f e  of only a few days. Studies u t i l iz in g  ra t liv e r apo fe rrit in  have 
shown a h a lf l i f e  of 50-75 hours for th is  fe r r it in  (Drysdale and Munro, 
1966).
T issue f e r r i t i n  appears to be taken up and degraded by the live r 
(Siimes and Dallman, 1974; Unger and Hershko, 1974), probably by a 
process of receptor mediated endocytosis (Mack et a l, 1983; Morgan and 
Baker, 1986). The fe r r it in  is  degraded by lysosomes, either to it s  
c o n s t itu t iv e  amino acids or to form haemosiderin (Bothwell et a l , 
1979). Thus haemosiderin appears to be the degradation product of 
fe r r it in .  I t  is  formed w ith in secondary lysosomes by the protease 
induced decomposition of the fe r r it in  molecule (R ichter, 1984). Within 
the lysosomes, the so lu b iliz in g  protein coat of fe r r it in  is  degraded, 
resu lting  in the water insolub le aggregates of hydrated iron oxide and 
organic constituents that make up haemosiderin (Bothwell et a l,  1979; 
Harrison et a l , 1980). Recently i t  has been shown that ascorbate can
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delay the t ra n s it io n  o f f e r r i t i n  in to  haemosiderin (Bridges and 
Hoffman, 1986).
The r a t io  o f f e r r i t i n  to haemosiderin in  storage organs varies 
according to the amount of iron present. At lower concentrations, 
fe r r it in  predominates but at higher concentrations most iron is  found 
as haemosiderin (Shoden et a l , 1958). Haemosiderin deposits are used 
as a h is to log ic  means of assessing the size of the body iron stores.
1.6.3. Serum fe r r it in
I t  was not surprising to find  fe r r it in  present in the c ircu la tion  in 
s ituations of damage to organs containing large amounts of fe r r it in ,  
for example hepatic necrosis (Bothwell et a l , 1979; Worwood, 1986). 
The development of sen s itive  immunological techniques to measure 
fe r r it in  brought with them the find ing of fe r r it in  in  the c ircu la tion  
of normal healthy ind iv idua ls (Addison et a l,  1972; Worwood, 1986). 
This serum fe r r it in  has been shown to be d iffe ren t from tissue fe r r it in  
in a number of ways.
Serum f e r r i t i n  has a very low iron  content. Immunologically i t  
resembles liv e r or spleen fe r r it in  and is  r ic h  in  L subunits (Worwood, 
1986). I t  has been found that a high proportion of fe r r it in  in  normal 
serum binds to concanavalin A, a le c t in  which forms complexes with 
polysaccharides and glycoproteins (Worwood et a l,  1979). This finding 
suggests that the range of is o fe r r it in s  of serum fe r r it in  is  the re su lt
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of g lycosylation of fe r r it in  and isnot due to variable proportions of H 
and L subunits, as is  the case for tissue fe r r it in  (Worwood, 1986). 
Another point of d ifference between serum fe r r it in  and tissue fe r r it in  
is  the ir rate of clearance from the c ircu la t ion , with serum fe r r it in  
being c lea red  from the c ir c u la t io n  at a slower rate than tissue 
fe r r it in  (Worwood, 1982). This d ifference too may re su lt  from the fact 
that serum fe r r it in  is  glycosylated.
The orig in  of serum fe r r it in  is  not c le a r .  While a l l  body c e l ls  
probably secrete fe r r it in ,  the liv e r and RES appear to be the main 
source of serum fe r r it in  production (Mack et a l , 1981). The orig in  of 
serum fe r r i t in  and the is o fe r r it in s  present in serum also d iffe r in 
d iffe ren t states of health. In normal ind iv idua ls much of the serum 
fe r r it in  is  glycosylated and th is  suggests secretion of fe r r it in  is  
possib ly from phagocytic c e lls  degrading haemoglobin (Worwood, 1986). 
A re ticu loendothe lia l c e ll o r ig in  is  supported by experiments performed 
in ra ts in which the entry of fe r r it in  into the plasma was followed 
with rad io iron  (Siimes and Dallman, 1974). However, in conditions of 
tissue damage another mechanism becomes important, that of the d irect 
release of ce llu la r  fe r r it in  through damaged ce ll membranes (Prieto et 
a l , 1975). Supporting th is  is  the f in d in g  in  p a t ie n ts  w ith  
fe r r it in a e m ia  due to liv e r necrosis, of very l i t t l e  of the plasma 
fe r r it in  binding to concanavalin A (Worwood et a l , 1979).
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Serum fe r r it in  appears to be cleared exclusively by hepatic parenchymal 
c e lls .  This occurs by a sp ec ific  receptor mediated process (Mack et a l , 
1983; Morgan and Baker, 1986).
Under normal circumstances the amount of fe r r it in  secreted into the 
c ircu la t io n  is  thought to be representative of the amount of fe r r it in  
synthesized in  the major iron storage s ites  of the body, namely the RES 
and the live r (Finch et a l , 1986). This close re la tionsh ip  between 
serum fe r r it in  leve ls and the amount of storage iron in the body is 
used c l in ic a l ly  in that, taken in conjunction with other parameters, 
measurement of serum fe r r it in  allows for d iscrim ination between simple 
iron depletion, iron de fic ien t e ry th ropo ies is  and iron  d e fic ien cy  
anaemia (Bothwell et a l,  1979). Also, i t  provides a non-invasive and 
moderately accurate way of assessing the tota l amount of iron stored in 
the body (Worwood, 1980).
The c h ie f  r e s t r ic t io n  to the c l in ic a l use of the plasma fe r r it in  
concentration for assessing iron nutrition  is  the fa c t  tha t i t  is  
influenced by other factors. Concentrations higher than ju s t if ie d  by 
the amount of stored iron are found in  acute and chronic in fections 
(Baynes et a l,  1986a; 1986b), inflammation (Baynes et a l, 1986a;
Baynes et a l , 1987a), neoplastic conditions (Bezwoda et a l , 1985; 
Worwood, 1986), heavy alcohol ingestion (Meyer et a l, 1984), liv e r 
disease (Worwood, 1986) and after unusually heavy exercise (Taylor et 
a l , 1987). A ra ised serum fe r r it in  concentration is  thus a re la t iv e ly  
non-specific find ing in c l in ic a l s itua tions. However, a low plasma
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f e r r it in  concentration of less than 12 ug/1 can only be due to iron 
deficiency.
1.6.4. The fe r r it in  receptor
The fe r r it in  receptor has been described in  guinea pig reticu locytes 
(Pollack and Campana, 1981; B ligh t and Morgan, 1983), ra t  hepatocytes 
(Mack et a l , 1983) and human placental c e lls  (Takami et a l, 1986). 
However it s  precise physiological ro le  remains unclear. I t  has been 
suggested that the fe r r it in  receptor may transfer iron from fe r r it in  to 
haem in the mitochondria (U lv ik, 1982).
Most re ce n t ly  i t  has been suggested that the fe r r it in  receptor on 
hepatocytes may serve to take up fe r r it in  released from Kupffer ce lls  
(Kondo et a l , 1988; S ib i l le  et a l,  1988). In th is  setting fe r r it in  
may function as an intrahepatic ca rrie r of iron between Kupffer ce lls  
and hepatocytes. I t  can also be seen that the fe r r it in  receptor on the 
hepatocyte, by binding fe r r it in  released by the Kupffer c e l l ,  may 
account for the resistance of the liv e r  to iron deficiency, as well as 
the su scep t ib ility  of the live r to iron overload (S ib il le  et a l , 1988).
1.6.5. Red ce ll fe r r it in
While erythrocytes contain both H and L is o fe r r it in s ,  the fe r r it in  
w ithin erythrocytes has been found to be approximately ten times more 
re a c t iv e  w ith  antibody to heart fe r r it in  than to spleen fe r r it in
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(Peters et a l , 1983). The two is o fe r r it in s  appear to have d iffe rent 
metabolic functions w ithin erythroid c e lls .  The ac id ic  H is o fe r r it in  
appears to be an intermediate in the transfer of iron from the plasma 
membrane to the mitochondria for incorporation into haem (Cazzola et 
a l , 1983). The basic L is o fe r r it in  w ithin the erythrocyte acts as an 
in tra ce llu la r depot of iron which is  in excess of that required for 
haem synthesis. I t  also re f le c ts  changes occurring in tissues in iron 
deficiency and iron overload (Cazzola et a l , 1983; Peters et a l,  
1983).
1.7 IRON RELEASE FROM RETICULOENDOTHELIAL (RE) CELLS AND HEPATOCYTES
1.7.1. Introduction
Under normal circumstances, the amount of iron transferred from plasma 
to c e lls  each day is  balanced by an equal amount returning in the 
opposite d irection  (Morgan, 1981). Compared to what is  known about 
iron uptake by c e lls ,  re la t iv e ly  l i t t l e  is  understood about the events 
and mechanisms o f iron  re lease from c e lls ,  and about the factors 
in fluencing th is  iron re lease.
The major source  o f iro n  r e tu r n in g  to  the plasma is  the 
reticu loendothe lia l system (Morgan, 1981). Thus much of the research 
into iron release from c e lls  has been performed using the RE c e ll.  The
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l i v e r  and g a s tro in te s t in a l mucosal c e l ls  make a sm aller but
s ig n if ic a n t  co n tr ib u t io n  to plasma iron  (Morgan, 1981). This 
d iscuss ion  w i l l  concentrate on iron  re le a se  from RE c e l ls  and 
hepatocytes to transfe rrin .
1.7.2. Iron release to apotransferrin
After donation of it s  iron to c e lls  by a process of receptor mediated 
endocytosis, transfe rrin  is  released as apotransferrin from the c e lls  
to which i t  has donated it s  iron (Morgan, 1981; Huebers and Finch, 
1987). Apotransferrin is  then availab le to bind iron and be involved 
in many more plasma to c e ll cycles, as is  indicated by it s  long plasma 
ha lf l i f e  of 7-10 days (Katz, 1961). Transferrin iron is  p rin c ip a lly  
directed to red c e ll precursors in the bone marrow. Iron released from 
RE c e lls  in vivo is  bound randomly by any availab le vacant transferrin  
iron-binding s ite , both on monoferric transferrin  and apotransferrin 
(Groen et a l , 1982). Iron released from iso lated  ra t  hepatocytes also 
binds randomly to any empty iron-binding s ites  on transferrin  (Young, 
1982). Since d ife r r ic  transfe rrin  is  a better iron donor in v itro  than 
monoferric transferrin  (Huebers et a l , 1983a), i t  is  l ik e ly  that in 
vivo, transferrin  must acquire 2 atoms of iron before i t  becomes an 
e ffe ctive  iron donor (Young and Bomford, 1984).
Much debate ex ists as to whether apotransferrin binds iron at the ce ll 
membrane or ex tra ce llu la r ly  at a s ite  d is ta l to the c e ll membrane. 
C lin ic a l observations are in favour of an active mechanism regulating
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iron release from c e lls ,  since iron is  released from RE c e lls  and ce lls  
of the gastro in testina l tra c t in proportion to body needs. However 
iron is  retained in RE c e lls  and gut mucosal c e lls  in the anaemia of 
chronic disorders despite a low plasma iron and transferrin  saturation 
(Roeser, 1980; Lee, 1983). In contrast, proportionately small amounts 
of iron are held up in the RE c e lls  and gut mucosal c e lls  re la t iv e  to 
the s tr ik in g  overload of parenchymal c e lls  and plasma transferrin  in 
id io p a th ic  haemochromatosis (B rin k  e t a l , 1976). These two 
disturbances of ce llu la r  iron handling appear to suggest that iron 
release or retention is  an active process since in both of them iron is  
re ta in ed  or re leased  from c e l ls  despite s ig n ific an t concentration 
gradients.
The mechanism of iron release from the liv e r was investigated using the 
iso lated perfused ra t  liv e r and ra t  hepatocyte suspensions (Baker et 
a l , 1977). I t  was found that the addition of apotransferrin to a 
transfe rrin -free  medium produced an increase  in  the ra te  of iron  
release from both types of preparations. However, other iron chelators 
such as c itra te  and desferrioxamine were also shown to be e ffective  as 
m obilizers of ce llu la r  iron. This suggested that transferrin  may be 
function ing  in  a n o n -sp e c if ic  way by p rov id ing  an iron -b ind ing  
component in the ex trace llu la r f lu id  which can bind iron after it s  
release from the c e l l .  A lte rna tive ly , the c itra te  and desferr ioxamine 
may aid iron release by a d iffe ren t mechanism than that of transferrin  
(see section 1.9.).
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In favour of apotransferrin acting as a passive acceptor of iron, was 
the find ing of no spec ific  receptors for apotransferrin on hepatocytes 
(Young and Aisen, 1981), a conclusion also reached by others using the 
in tac t perfused ra t liv e r (Baker et a l , 1980). However, s p e c if ic  
a p o tra n s fe r r in  recep to rs  have been id e n t i f ie d  on cu ltu red  r a t  
peritoneal macrophages (Nishisato and Aisen, 1982; Saito et a l , 1986). 
Iron b-inding to these recep to rs  was not in fluen ced  by d ife r r ic  
transfe rrin  but was displaced by cold apotransferrin (Nishisato and 
Aisen, 1982). In addition i t  has been reported that the incubation of 
iron loaded macrophages in  media containing apotransferrin resulted in 
the progressive saturation of the apotransferrin with iron (Saito et 
a l , 1986). The im plication of these studies was that apotransferrin 
receptors existed to which apotransferrin bound in  it s  acquis ition  of 
iron from c e lls .  In these studies, macrophages were found to release 
considerable amounts of iron as fe r r it in ,  ra is in g  the question as to 
whether the resu lts  obtained were consequent upon leakage occurring 
from the c e lls  as a re su lt  of their decreased v ia b il ity .  Indeed a 
recent study fa i le d  to  id e n t ify  the presence of apo tran s fe rr in  
receptors at physiological pH of 7.4 on cultured human blood monocytes 
(Baynes et a l , 1987b). In th is  study i t  appeared that the small amount 
o f  a p o t r a n s fe r r in  b in d in g  tha t d id  occur re su lte d  from iron  
contamination. I t  is  possible that the discrepancy between these 
find ings and the previous findings of apotransferrin receptors on ra t 
peritoneal macrophages may be due in  part to minor degrees of iron 
contamination in  the la tte r studies.
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On current evidence i t  seems un like ly  that apotransferrin receptors are 
required in the normal transport of iron from RE c e lls  to plasma. Were 
apotransferrin receptors to be of physiological s ign ificance , i t  might 
be antic ipated that they would be present on RE c e lls  in large numbers, 
since RE c e lls  deliver as much iron da ily  into the plasma as is  removed 
by erythroid precursors (Baynes et a l , 1987b).
1.7.3. The e ffe c t of a saturated transferrin
Since transfe rrin  is  the major iron binding protein in the plasma, 
studies have been performed whereby the saturation of transferrin  has 
been a ltered in  an attempt to further elucidate factors a ffecting  iron 
release from c e lls .  These studies have also attempted to determine the 
ro le  played by transfe rrin  in iron release from c e lls .  Such studies in 
the past have u t il iz e d  the parenteral in fusion of elemental iron to 
saturate transferrin  and thus block transferrin  binding s ite s  and iron 
release. The re su lts  of these studies have not been in agreement with 
one another. In one study, iron as iro n -n it r ilo t r ia c e t ic  acid was 
administered to ra ts  in amounts which exceeded the availab le binding 
s ites  of transfe rrin  (L ipsch itz et a l , 1971c). This resulted in marked 
hyperferraem ia and d im in ished re le a se  by RE c e l ls  of iron from 
subsequently infused damaged red c e lls .  Studies in dogs found that 
there was l i t t l e  d ifference in the pattern of iron release from RE 
c e lls  after heat damaged erythrocytes were injected into control dogs 
and dogs in which the plasma transferrin  was saturated by in jecting  
fe r r ic  ammonium c itra te  ( F i l le t  et a l , 1974). In a th ir d  study,
61
fe rrous ammonium sulphate was infused into ra ts  to saturate plasma 
transferrin  and in that study the in a b il ity  of RE c e lls  and hepatocytes 
to re le a se  iron  in  the tra n s fe r r in -s a tu ra te d  animal was again 
demonstrated (Bergamaschi et a l , 1986).
In addition to discordant resu lts  being obtained, another problem of 
these studies has been the ir use of infused elemental iron to saturate 
transfe rrin . This method of saturating transferrin  is  unphysiological 
and may re su lt  in super saturation o f t ra n s fe r r in  w ith consequent 
c ircu la t in g  free iron present in the plasma. Thus the resu lts  of these 
studies must be viewed with suspicion.
One aspect o f the experimental work of th is  thesis is  aimed at 
saturating transfe rrin  in  a more physiological fashion and evaluating 
the re g u la t io n  o f RE and hepatic parenchymal iron release in the 
presence of a physio log ica lly  saturated transfe rrin .
1.7.4. The ro le  of caeruloplasmin and ascorbic acid
Release of iron from c e lls  may also be dependent upon the a v a ila b ility  
of caeruloplasmin. When the liv e rs  from copper-deficient baby pigs or 
adult dogs were perfused with serum free solutions containing human 
apotransferrin, l i t t l e  or no iron was released to the protein. However 
incorporation of caeruloplasmin in to  the perfusing medium resulted in a 
ra p id  e ff lu x  of iron from the liv e rs , the iron appearing bound to 
transferrin  (Osaki et a l , 1971). Although the deleterious effects of
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copper deficiency on iron metabolism and the capacity of caeruloplasmin 
to correct these e ffects have long been appreciated, the mechanism by 
which caeruloplasmin acts remains controversial (Williams et a l , 1974). 
I t  may be that iron release from c e lls  depends on it s  oxidation from 
the fe rrous to the f e r r ic  form, the ox ida tion  s ta te  bound by 
transfe rrin , and that th is  change is  dependent upon the ferroxidase 
a c t iv ity  of caeruloplasmin (Frieden and Osaki, 1974).
Ascorbic acid also appears necessary for the release of iron  from 
c e lls ,  possibly by maintaining iron in  i t s  appropriate oxidation state 
to be bound by transfe rrin . Ascorbate deficiency exerts a marked 
e ffe c t on the metabolism and storage of iron, as evidenced by c lin ic a l 
studies in  scorbutic Black patients (Bothwell et a l , 1964), as well as 
in  guinea pigs (Banerjee and Chakrabarty, 1965; L ipsch itz et a l,
1971a). These studies showed that scurvy resu lted in a block in  RE 
iron release associated with a s h if t  of iron stores from fe r r it in  to 
haemosiderin and a reduction in serum iron leve ls . Ascorbate treatment 
in  scorbutic patients resulted in a dramatic increase in serum iron 
concentration (Bothwell et a l , 1964) followed by an increase in serum 
fe r r it in  leve ls (Cohen et a l, 1981; Chapman et a l,  1982). Other 
studies i l lu s t r a t in g  the r o le  tha t a sco rb ic  a c id  p lays in  iron  
metabolism showed that while the plasma iron concentration is  elevated 
in Black South Africans with dietary s iderosis, such patients that had 
coexistent ascorbic acid deficiency were found to have normal or even 
low plasma iron concentrations. Hyperferraemia occurred promptly 
fo llow ing administration of ascorbic acid to these patients (Wapnick et
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a l , 1970). The ascorbate deficiency in iron overload resu lts  from it s  
accelerated oxidative catabolism (Lynch et a l , 1967).
Recent in v itro  studies in K562 c e lls  have shown that ascorbate delays 
the trans ition  of f e r r i t i n  iron  in to  the in s o lu b le  haemosiderin 
compartment, and provided evidence that th is  delay is  associated with 
expansion of the chelatable low molecular weight in tra ce llu la r iron 
pool (Bridges and Hoffman, 1986).
1.8 THE LOW MOLECULAR WEIGHT (LMW) INTRACELLULAR IRON POOL
1.8.1. Introduction
There is  a considerable amount of information availab le on the ce llu la r 
acqu is ition  of iron, the release of iron from it s  transport protein 
transfe rrin , and i t s  incorporation into it s  f in a l biochemical form. 
However the pathway that iron actua lly  fo llows after it s  release from 
transfe rrin  and prior to it s  reaching it s  target in the ce ll is  not 
well understood. I t  appears tha t iron  passes through a la b i le ,  
in tra ce llu la r  iron pool at least p a rt ia lly  comprised of low molecular 
weight complexes, and that th is  pool can be tapped by extrace llu lar 
complexing agents. The concept of an in tra ce llu la r pool of LMW iron 
ligands is  appealing as i t  serves to ra t io na lize  in tra ce llu la r iron 
exchange (Jacobs, 1977). However d irect evidence for th is  pool has 
un til recently  been largely speculative.
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1.8.2. Characterization
In d ire c t evidence for a highly chela table form of iron which is  a 
normal metabolic intermediate in reticu loendothe lia l c e lls  was provided 
by a number o f s tud ies  using the che la to r desferrioxamine (DFO) 
(Cumming et a l , 1967; Karabus and F ie ld ing , 1967; L ipsch itz et a l , 
1971b). A reduction in iron flow through the reticu loendothe lia l ce ll 
produced by suppression of erythropoiesis reduced the amount that could 
be chelated (L ipsch itz et a l,  1971b) and an increase in iron flow 
induced by haemolysis increased chelation (Cumming et a l , 1967). Rat 
experiments confirmed that fe r r it in  and haemosiderin were not important 
d irect donors of iron to DFO and that compounds in the pathway between 
storage compounds and transfe rrin  are the probable source of the iron 
chelated by DFO (L ipsch itz et a l , 1971b).
Within the erythrocyte, evidence was found for the existence of short­
lived  nonhaem intermediates. Zail and coworkers (1964) presented 
serum-bound S^Fe to cu ltu re s  o f human marrow c e l ls  and found a 
non ferritin  non-haemoglobin precursor from which iron  was ra p id ly  
removed for haem synthesis. In marrow cultures from iron-defic ien t 
patients there was a transient lab e llin g  of the intermediate fraction  
before complete in co rp o ra tion  in to  haemoglobin took place. The 
presence of th is  soluble in tra ce llu la r iron compound in erythroid c e lls  
tha t served as a source of iron for haemoglobin and fe r r it in  was 
confirmed by other workers (Primosigh and Thomas, 1968).
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More recent data regarding the in tra ce llu la r  la b ile  iron pool in non- 
erythroid c e lls  was obtained from experiments using cu ltu red  Chang 
c e lls  as a model system. About 30% of the iron taken up by these ce lls  
from transferrin  is  membrane bound and the remainder is  found in the 
cytosol. Chang c e lls  synthesize fe r r it in  active ly  in response to an 
iron load and most of the cytosol iron is  present in th is  form (White 
e t a l , 1976a). However about 35% of th is  iron is  in a non-haem, 
non fe rritin  d ia lyzable form (White et a l , 1976a). Gel f i l t r a t io n  of 
the membrane-free supernatant after centrifugation of the sonicated 
Chang c e lls  showed that the LMW fraction  could be read ily  chelated by 
DFO, EDTA or transfe rrin . When Chang c e lls  were labe lled  with 59Fe 
transfe rrin  so that the rad io iron  was normally d istributed through the 
c e l l  f r a c t io n s ,  subsequent tran s fe r o f the cu ltu re  to a medium 
containing DFO resu lted in rap id  iron depletion of the ce ll (White et 
a l , 1976b). The 59pe fe r r it in  content f e l l  more rap id ly  than did the 
LMW 59p6j but as Qpo has been shown not to chelate fe r r it in  iron 
d ire c t ly , m obilization presumably occurred via the LMW pool. Similar 
m obilization of in tra ce llu la r iron was observed when the c e lls  were 
incubated with transfe rrin , the amount removed being inversely re lated 
to the transferrin  saturation (White et a l , 1976b).
The incubation of pure cultures of human polymorphonuclear leukocytes, 
lymphocytes and monocytes under the same conditions as those used in 
Chang ce ll experiments showed that despite wide differences between the 
d iffe ren t c e ll types and variations in disease states, "cytosol" iron 
was present in both fe r r it in  and n o n - fe r r it in  forms (Summers and
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Jacobs, 1976). Thus, while a variety of c e lls  appeared to contain th is 
LMW iron pool which was eas ily  ava ilab le for uptake by fe r r it in ,  haem, 
transfe rrin  and chelators, the evidence for i t s  existence was ind irect 
and it s  chemical nature was poorly characterized un til recently.
1.8.3. Chemical nature of the LMW pool
For a long while the chemical nature of the intermediate or la b ile  iron 
pool was unknown. I t  appeared to be a low molecular weight complex of 
iron or a mixture of such complexes (Jacobs, 1977). The ligands in 
th is  LMW pool could have included almost any of the LMW species present 
in the cytosol (Pollack et a l , 1985). A reducing agent has been found 
to be necessary in the transfer of iron from transferrin  to fe r r it in  
(M ille r and Perkins, 1969) and i t  was postulated that th is  agent was to 
be found in  the LMW pool. The reducing agent functions to form an 
intermediate ferrous chelate with iron once iron has been freed from 
transfe rrin . I t  ensures that the iron is  availab le in the ferrous 
state for uptake by fe r r it in  (M ille r and Perkins, 1969). Ascorbic acid 
appears to f u l f i l  th is  ro le  e ffe c t iv e ly  and c itra te , sugars, amino 
acids and nucleotides may a l l  function as intermediate ligands in iron 
transfer. Id en tifica tion  of these intermediate iron compounds not only 
depends on the ir chemical characterization but also depends on their 
a b il it y  to display the appropriate functions. While fe r r ic  c itra te  can 
be u t il iz e d  d ire c t ly  by the re ticu locy te  and the same is  true for a 
number of LMW chelates such as n itr ilo a ce ta te  (Morgan, 1971), these 
chelates are however nonphysiologic.
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The f i r s t  d irect demonstration of a LMW iron pool in the ce ll was by 
Pollack and Campana (1980). This was achieved using a buffer with 
minimal a f f in ity  for metal and without adding chelate. This LMW iron 
in the re ticu locy te  has recently been characterized (Pollack et a l , 
1985). On thin layer chromatography th is  LMW iron is  distinguishable 
from the iron complexes of a variety of nucleotides, sugars and amino 
acids. On paper chromatography i t  comigrates with a 250nm absorbing, 
o rc ino l-pos itive  m aterial. The eluted count peak contains phosphorous. 
Continuously gassing the buffer used in  these experiments with nitrogen 
improved recovery of the LMW iron, suggesting that the iron is  in the 
ferrous oxidation state (Pollack et a l , 1985). One of the aims of the 
present investigation is  to further characterize the nature of the iron 
in th is  la b ile  intermediate pool.
1.8.4. C lin ica l s ign ificance
The in t r a c e l lu la r  LMW iron  pool occupies a fo ca l p o s it io n  in 
in tra ce llu la r  iron metabolism. I t  provides iron for mitochondria which 
are the s ite  of haem synthesis either for mitochondrial cytochromes, 
fo r extram itochondrial cytochromes such as cytochrome P450 and for 
specia lised proteins such as haemoglobin or myoglobin (Jacobs, 1977; 
Bomford e t a l , 1986). A wide variety of processes, such as DNA
synthesis (Hoffbrand et a l , 1976) are inh ib ited  by DFO and may be 
assumed to depend on the a v a ila b ility  of iron in the LMW iron pool. In 
addition a l l  c e lls  contain non-haem enzymes which appear to depend on 
an adequate tissue iron status for the ir function (Finch et a l , 1976),
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and presumably such enzymes must depend on the m etabolically functional 
in tra ce llu la r la b ile  iron pool.
In addition fe r r it in  synthesis is  induced by enlargement of th is  iron 
pool (Lynch et a l , 1974; Young et a l , 1985; Bomford et a l , 1986), a 
find ing that is  addressed by the present investigation. The ce llu la r 
basis for the regu lation of fe r r i t in  synthesis has re c e n t ly  been 
delineated (see section 1.6.2.2. previously). This may provide an 
explanation for the find ing  that enlargement of the LMW pool appears to 
be a transien t phenomenon, as evidenced by the fact that with the 
passage of time, less iron is  present in th is  form and more is  present 
in the form of functional and storage compounds (Bridges and Cudkowicz, 
1984; Young et a l , 1985; Bomford et a l , 1986).
F in a l ly ,  the in te ra ction  of th is  small molecular weight pool with 
ex trace llu la r transfe rrin  and thus sim ilar pools in  other t issues 
provides a mechanism whereby an equilibrium  can be established not only 
between the various metabolic processes in the c e ll but also between 
d iffe ren t organs in the body (Jacobs, 1977).
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1.9 CHELATABLE IRON AND CHELATING AGENTS
1.9.1. Introduction
Evo lu tion  has provided e f f i c ie n t  mechanisms for the acqu is ition, 
transfer and storage of iron, but has not provided mechanisms for 
promoting the excretion of excess iron. The c lin ic a l consequence of 
continued iron accumulation is  the abnormal function of a number of 
organs, the most important of which are the heart, liv e r  and pancreas. 
While the manifestations of chronic iron overload are p o te n t ia lly  
curable by the e ffe ctive  m obilization of storage iron by phlebotomy 
(Easley et a l , 1972; Short et a l , 1981), the e ffective  administration 
of iron chelators such as desferrioxamine can prevent and even reverse 
the c l in ic a l manifestations of iron overload (Hershko and Weatherall, 
1988).
In normal subjects, most of the body iron is  unavailable for chelation. 
Iron in haemoglobin, representing over two th irds of a l l  iron, is  
unavailable for chelation and transferrin-bound-iron is  a poor source 
of iron for chelation. The most l ik e ly  sources of chelatable iron 
include that stored in  tissues in the form of fe r r it in  or haemosiderin 
and the la b ile  iron compartment constitu ting  the LMW iron pool that is  
in  e q u ilib r iu m  w ith fe r r it in  (Hershko and Weatherall, 1988). The 
increased a v a ila b ility  of iron for chelation found in conditions of 
increased catabolism of fe r r it in  and haemoglobin-bound iron (Cumming et 
a l , 1967; Karabus and F ie ld ing , 1967; L ipsch itz et a l , 1971b) lent
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support to the existence of a LMW chelatable iron pool. That th is  pool 
rather than fe r r it in  or haemosiderin is  the most lik e ly  source of iron 
bound by chelators has been confirmed by ra t  experiments (Lipsch itz et 
a l , 1971b). A consequence of the a cce ss ib ility  of the LMW pool to 
che la to rs  is  tha t knowledge of the mechanism o f action of these 
chelators can be u t il iz e d  in an attempt to characterize the nature of 
the iron in th is  LMW pool. I t  is  against th is  background that various 
chelators have been employed in the investigations performed in th is  
thesis. What fo llows is  a short overview of the chelators u t iliz e d  in 
th is  study.
1.9.2. Desferrioxamine (DFO)
DFO is  a co lou rless c ry s ta llin e  substance produced by Streptomyces 
P ilosus. I t  consists of a chain of three hydroxamic acids terminating 
in  a free amino acid group, which enables i t  to form sa lts  with organic 
and inorganic acids (Keberle, 1964). I t  is  capable of combining with 
fe r r ic  iron at a 1:1 molar ra t io  and with a s ta b il ity  constant of 10 1^. 
The a f f in it y  of DFO for ferrous iron and other metal ions such as zinc, 
copper, magnesium and calcium is  much lower.
There are fundamental differences in  the behaviour of DFO as compared 
to ferrioxam ine, the DFO-iron complex. As a re su lt of the change in 
configuration fo llow ing interaction  with iron, ferrioxamine becomes an 
extremely stable compound res is tan t to enzymatic degradation (Meyer- 
Brunot, 1967). In contrast to DFO which is  capable of penetrating
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various tissues, ferrioxamine is  d istributed  in  the extrace llu la r space 
and is  unable to penetrate c e lls .
DFO is  able to in te ra c t  in  v it r o  w ith iron  located in cultured 
hepatocytes (White et a l , 1978; Octave et a l , 1983; O'Connell et a l , 
1985), cardiac c e lls  (Sciortino et a l, 1980; Link et a l,  1985) and 
monocytes (Esparza and Brock, 1981). D irect evidence for the ce llu la r 
uptake of DFO is  ava ilab le only in hepatocytes (O'Connell et a l, 1985) 
where i t  in teracts in s itu  with hepatocellular iron which is  then 
excreted via the b il ia r y  tract. The contribution of RE c e lls  to DFO- 
induced iron excretion is  lim ited (Hershko et a l , 1973; Pippard et a l , 
1982; Kim et a l , 1985), and i t  is  not en tire ly  clear as to whether RE­
derived iron is  chelated by DFO w ith in RE c e lls  or fo llo w in g  i t s  
release into the plasma (Pippard et a l,  1982). The iron derived from 
the RES by DFO is  subsequently excreted via the urine. Urinary DFO is  
excreted by both glomerular f i l t r a t io n  and tubular secretion, whereas 
ferrioxamine is  partly reabsorbed fo llo w in g  glomerular f i l t r a t io n  
(Peters et a l , 1966).
The gastro in testina l absorption of both DFO and ferrioxamine is  poor 
(Keberle, 1964). Oral administration of DFO is  e ffective  in blocking 
the in tes tina l absorption of inorganic iron but has only a small e ffect 
on urinary excretion. The in tes tin a l absorption of o ra lly  administered 
iron is  inh ib ited  by the parenteral administration of DFO.
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The rap id  clearance of DFO from plasma, it s  e ffective  catabolism and 
it s  active tubular secretion severely lim it  the effectiveness of single 
bolus in jections given at long in te rva ls. However the fact that i t  is  
d istribu ted  in over 60% of the tota l body volume indicates that i t  has 
access to in tra ce llu la r  compartments in diseases where interaction  with 
chelatable in tra ce llu la r iron is  benefic ia l (Hershko and Weatherall, 
1988).
1.9.3. Pi ethylenetriamine penta-acetic acid (DTPA)
DTPA is  a synthetic compound belonging to the group of polyanionic 
amines. I t  was f i r s t  used for the treatment of iron overload in  humans 
by Fahey and coworkers (1961). I t  was subsequently shown to be as 
e ffe c tive  as DFO in promoting urinary iron excretion (Bannerman, 1962). 
I t  is  highly soluble in water but is  unable to penetrate c e lls .  Iron 
chelated by DTPA is  derived from RE c e lls  and is  excreted so le ly  in the 
u r in e  (Hershko e t a l , 1978a). I t  is  in e f f e c t iv e  by o ra l 
adm inistration. Its  highest a f f in it y  is  for fe r r ic  iron (Bridges and 
Cudkowicz, 1984). Calcium-DTPA is  well to lerated when administered by 
slow subcutaneous or intravenous in fusion. Zinc depletion after 
prolonged DTPA treatment is  a s ig n if ic a n t ' problem, but i t  can be 
prevented by oral zinc supplementation.
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1 .9 .4 .  2 , 2 'b ip y r id i  ne
Th is is  a hydrophobic iron  che la to r which p a r t it io n s  into ce ll 
membranes and binds ferrous iron as i t  passes through th is  l ip id  
environment (Nunez et a l , 1983; Morgan, 1983a). The b ipyrid ine-iron 
complex is  however hydrophilic and unable to cross c e l l  membranes 
(Nunez et a l , 1983; Morgan, 1983a; Bridges and Cudkowicz, 1984). 
2 ,2 'bi pyridine is  also able to lim it  erythroid iron uptake by blocking 
transmembranous ferrous iron transport from the a c id if ie d  endocytic 
vesic le  in to  the c e ll cytosol and returning the bipyrid ine-ferrous iron 
h y d ro p h ilic  complex back to the ex trace llu la r environment (Morgan, 
1983a; Baynes et a l , 1988a). The iron-chelator is  released from the 
c e ll by a process which is  very sim ilar to that of transferrin  release 
from c e lls  with respect to k ine tics  and s e n s it iv ity  to incubation  
temperature and the e ffe cts  of metabolic inh ib ito rs  and other chemical 
reagents (Morgan, 1983a).
There is  some disagreement as to whether 2 ,2 'b ipyrid ine acts w ithin the 
cytosol in  it s  chelation of ferrous iron. Morgan (1983a) hypothesized 
that 2 ,2 'b ipyrid ine blocked ce ll iron uptake by gaining entrance to the 
cytosol, chelating ferrous iron and then d iffu s ing  out of the c e ll.  
The r e s u lt s  o f in v e s t ig a t io n s  by Nunez and coworkers (1983) were 
incompatible with the hypothesis of 2 ,2 'b ipyrid ine chelating iron from 
the cytosol compartment. They showed that the chelator pa rtit ions into 
the membrane compartment of re ticu locy tes, chelates membrane-associated 
iron and then ex its into the ex trace llu la r m ilieu without entering the
74
c e l l  cy toso l in  the process. The change in so lu b ility  when the 
chelator binds iron affords an explanation for the fast onset of the 





Much is  known of the nature of transferrin  iron delivery to erythroid 
and other c e lls  (Morgan, 1981; Huebers and Finch, 1987). In contrast 
there is  a paucity of knowledge of the factors regulating RE iron 
metabolism and release. The rate of return of red ce ll derived iron, 
l ib e ra te d  from ca tab o lized  haemoglobin in  the RE c e l l ,  to the 
c ircu la t ion  is  governed by partition ing  between an early release pool 
and a slow storage pool (Noyes et a l, 1960). The factors regulating 
th is  partition ing  are incompletely understood. Previous work involving 
the parenteral in fusion of elemental iron to block transferrin  binding 
s ites for iron suggested that ce llu la r  iron release was inh ib ited  in 
the presence of a highly saturated transferrin  (L ipsch itz et a l, 1971c;
Bergamaschi et a l , 1986). A c r it ic ism  of th is  work is  that the use of 
a p a re n te ra l in fu s io n  o f iro n  to  s a tu ra te  t r a n s f e r r in  is  
unphysiological in that i t  may have resu lted in super saturation of 
transferrin  with consequent c ircu la t in g  free iron being present.
In the current investigation the enteral administration of carbonyl 
iron  (Huebers et a l,  1986) was employed in  an attempt to saturate 
transfe rrin  in  a more physiological fashion. In addition, the effects 
on serum iron of sing le and repeated transfusions of heat damaged red 
c e lls ,  and of haemoglobin were investigated.
Radioiron-tagged heat damaged red c e lls  were employed for the study of 
RE behaviour in the s e tt in g  o f a lte re d  t ra n s fe r r in  sa tu ra tion s ,
77
enhanced erythropoiesis, prior in jection  of non-tagged haemoglobin and 
infusion of homologous tissue fe r r it in .  The nature of the rad ioiron 
derived from the heat damaged red c e lls  and held up in the RES as a 
consequence of a highly saturated transferrin  was characterized  by 
chromatographic analyses of splenic and hepatic extracts. Chelators 
with various modes of action were included in sp lenic and hepatic 
preparations to further characterize the in tra ce llu la r chelatable pools 
of rad io iron . F in a lly , the findings of the in v itro  inc lus ion  of 
ch e la to rs  in  sp len ic  and hepatic preparations were confirmed by a 
series of in vivo chelator studies.
A ll investigations included in  the study have been approved by the 
Animal Ethics Committee of the University of the Witwatersrand.
2.2. Sprague-Dawley ra ts
The study u t il iz e d  normal male Sprague-Dawley ra ts , weighing 250-300g 
each. A ll ra ts  were maintained on a standard commercial cube d iet 
(Epol, Johannesburg, South A fr ica ).
2.3. Carbonyl iron
2.3.1. Background
Carbonyl iron  is  a small p a r t ic le  preparation of highly purified  
m eta llic  iron. I t  is  in e rt and incapable of reacting with strong
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chelators of iron such as transferrin  and desferrioxamine (Huebers et 
a l , 1986). The manufacturing process involves the heating of gaseous 
iron  pentacarbonyl (Fe(C0)5)> which resu lts  in the deposition of 
m eta llic  iron as submicroscopic crysta ls that form microscopic spheres. 
The term "carbonyl" describes the abovementioned manufacturing process 
and not the composition of the iron p a rtic le s . When adm inistered 
o ra lly , carbonyl iron is  much less tox ic than ionized forms of iron 
such as ferrous sulphate (Crosby, 1978). The reason for th is  and the 
manner in  which the m e ta llic  pa rtic le s  of carbonyl iron are made 
ava ilab le for absorption and u t il iz a t io n  was not fu l ly  understood. A 
study recently undertaken to determine the mechanism of carbonyl iron 
absorption and the reason for i t s  lower to x ic ity  (Huebers et a l , 1986) 
revealed that so lu b iliza t io n  of carbonyl iron by gastric acid is  a 
prerequisite for i t s  subsequent absorption and that the slow rate of 
s o lu b i l iz a t io n  o f carbonyl iro n  re su lte d  in  i t s  more prolonged 
absorption and i t s  low to x ic ity . Once i t  has been so lub ilized  , the 
subsequent pathway of absorption of carbonyl iron by the in testina l 
mucosa and the amount absorbed is  sim ilar to that of ferrous ammonium 
sulphate (Huebers et a l, 1986). L i t t le  or no carbonyl iron is  absorbed 
in v itro  and in vivo unless i t  is  exposed to a pH of less than 2 
(Huebers et a l,  1986).
2.3.2. Administration
The carbonyl iron used was 3 to 4 /im in  p a rt ic le  s ize , of SF grade and 
was obtained from GAF Corporation, New York. Each dose of carbonyl
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iron  was adm in istered in  1 ml a c id if ie d  sa line pH 2.0. It was 
introduced into the stomachs of fasted ra ts  w ith an o liv e  tipped 
canula. On day 1, after an overnight fa s t during which time they had 
free access to water, the animals were fed 400mg of carbonyl iron, 
fo llow ed by 200mg carbonyl iron 24 hours la te r. The animals were 
fasted during th is  24-hour period, but had free access to water. Two 
animals were exsanguinated by cardiac puncture under anaesthesia at 
various time in terva ls after the f i r s t  and second doses of carbonyl 
iro n . The blood was separated by centrifugation and serum iron, 
unsaturated iron-binding capacity, tota l iron binding capacity and 
percentage sa tu ra tion  o f t ra n s fe r r in  were measured (International 
Committee for Standardization in Haematology (Iron Panel), 1978 a; b). 
The time period when near complete steady state transferrin  saturation 
occurred was determined.
2.4 Heat Damaged Red Ce lls  (HDRC)
Sim ilar time dependent studies examining the e ffects  of HDRC on serum 
iron concentration and transfe rrin  saturation were performed.
2.4.1. Preparation
HDRC were prepared after the method of L ipsch itz and coworkers (1971b). 
Blood removed from a donor ra t  was centrifuged at 2000 rpm for 20 
minutes, with the removal of plasma. The red c e lls  were washed twice 
in normal sa line and were then suspended in four times their volume of
80
a 1:1 mixture of isoton ic sa line and ACD (5g c i t r i c  acid, 13.8g sodium 
c itra te  and 13g dextrose per l i t r e  of so lu tion). The red c e lls  in the 
r e s u lt in g  s o lu t io n , w ith a haematocrit of ZQ%, were denatured by 
heating for 20 minutes in a water bath at 40°C.
2.4.2. Transfusion
The HDRC were transfused  v ia  the t a i l  vein w ith in  one hour of 
preparation. The e ffe c t of a sing le  transfusion of a 3 ml/kg 20% 
haematocrit so lution of heat damaged homologous erythrocytes and of 3 
repeated transfusions of 6 ml/kg of a sim ilar solution on serum iron, 
unsaturated iro n -b in d ing  capacity, tota l iron-binding capacity and 
percentage saturation of transferrin  was determined (In te rna tiona l 
Committee for Standardization in Haematology (Iron Panel), 1978a; b).
Animals were again exsanguinated by cardiac puncture under anaesthesia.
2.5. Radioiron tagging of erythrocytes
The haemoglobin of ra t  red c e lls  was uniformly labe lled  by repeated 
in jections of rad io iron  (59pe). These radioiron-tagged erythrocytes 
were then heat damaged as described and were employed for the study of 
RE and hepatic iron handling in various experimental settings.
Radioiron tagging of red c e lls  in vivo was accomplished as fo llows. 
Rats whose erythropoiesis was stimulated by removing 4 ml of blood by 
cardiac puncture on the sixth and f i f t h  days p r io r  to the f i r s t
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in jection  of rad io iron , were given an in i t ia l  intravenous in jection  of 
200yuCi 59pe as fe r r ic  ch loride. 50/uCi of 59pe as fe r r ic  chloride was 
administered every week thereafter. After su ff ic ie n t time had elapsed 
to permit uniform tagging, these ra ts  were bled under anaesthesia to 
obtain rad io labe lled  erythrocytes for the preparation of HDRC. Each 
animal was not venesected more than once a month.
2.6. Serum iron (SI) concentration
The SI concentration was determined u t i l iz in g  the method recommended by 
the International Committee for Standardization in Haematology (ICSH, 
1978a). I n it ia l ly  the plasma was a c id if ie d  with a mixture of 1 molar 
HC1 and 10% t r ic h lo r a c e t ic  acid in  order to d issociate the iron- 
transferrin  complex and to p rec ip ita te  proteins. The simultaneous 
addition of a 3% th io g ly c o llic  acid so lution ensured complete reduction 
o f the d is s o c ia te d  t r a n s f e r r in  ir o n  to  the fe r ro u s  form . 
Deproteinization is  an important step in measuring serum iron as i t  
removes substances such as haemoglobin, b iliru b in  and plasma lip id s  
which would otherw ise increase the optica l density of the plasma 
(Bothwell et a l , 1979). The op t ica lly  clear supernatant was then 
treated with buffered bathophenanthroline sulfonate and the absorption 
of the ferrous complex was measured at 535 nm. Two ml of a standard 
iron solution containing 40/jmol/l iron in 5 mmol/1 HC1» and two ml of 
d is t i l le d  water for a blank were treated in the same way as the serum 
samples. The serum iron  concen tra tion  was then ca lcu la te d  by
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m ultip ly ing by 40 the ra t io  of the d ifferences of the absorption of the 
test sample and the blank to the standard sample and the blank.
2.7. Unsaturated iron-binding capacity (UIBC)
This was measured u t i l iz in g  the method recommended by the International 
Committee for Standardization in  Haematology (ICSH, 1978b), and 
involved an adsorbent method in  which iron in excess of the binding 
capacity of transfe rrin  is  added. The compound used to saturate 
t ra n s fe r r in  was ra d io - la b e lle d  f e r r ic  ch lo r id e  in  a d ilu te  HC1 
so lution. Magnesium carbonate which strongly adsorbs the unbound ion ic 
iron was added, and the samples were centrifuged to remove the iron. 
The unsaturated iron-binding capacity was measured d ire c tly  by counting 
the r a d io a c t iv it y  present in  the supernatant. The ra t io  of the 
rad ioactive counts in the test sample to those o f two ml of the 
sa tu ra tin g  iron  so lu t io n  yie lded the UIBC value, after background 
a c t iv ity  was subtracted.
2.8. Total iron-binding capacity (TIBC)
The TIBC was calculated by summing the values obtained for serum iron 
concentration and UIBC. The TIBC re f le c ts  the level of transferrin  and 
gives the tota l number of iron binding s ites on the transport protein, 
while the serum iron concentration re f le c ts  the number of iron atoms 
actua lly  bound (Kimber et a l , 1983).
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2 .9 .  Percen tage  s a tu r a t io n  o f  t r a n s f e r r i n
Percentage saturation was calculated by m ultiplying the ra t io  of serum 
iron to tota l iron binding capacity (TIBC) by 100.
2.10. Analytica l 59pe organ d is tribu tion
Radioiron tagged HDRC were in jected in to  both control ra ts and into 
experimental ra ts  via the t a i l  vein w ithin one hour of preparation. 
The volume of tagged HDRC used was 3 ml/kg o f a 20% haematocrit 
so lu tion. This corresponded to a dose of iron of approximately 0.8 
mg/kg. At various time in terva ls after the in jection  of the tagged 
HDRC, ra ts  were anaesthetized, exsanguinated by cardiac puncture and 
washed out with normal sa line. The percentage d is tribu tions of 59pe n-n 
the l iv e r ,  spleen, blood, kidneys, and marrow was determined. The 59Fe 
a c t iv ity  of one ml of blood, both kidneys, one femur, and the spleen 
and l i v e r  were counted  in  a Packard Autogamma s c in t i l la t io n  
spectrometer model 5650 (Packard Autogamma Co., Downers Grove, 
I l l in o is ) .  Total marrow a c t iv ity  was estimated by m ultiplying the 
counts of one femur by 13 (Hershko et a l,  1972). The a c t iv ity  of the 
blood was calcu lated from the one ml of blood counted, assuming that 
the tota l blood volume of a ra t  is  65 ml/kg.
The organ d is tr ibu tion  of 59pe was assessed in experiments conducted 
both shortly after the in i t ia l  dose of carbonyl iron and at a time when 
steady state increased transferrin  saturation had been achieved. Organ
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d is tr ibu tion  of rad io iron  was also studied in animals that had enhanced 
erythropoiesis prior to tagged-HDRC in jec tion . The e ffe c t of prior 
in je c t io n ,  one hour before tagged HDRC infusion, of an equivalent 
amount of non-tagged free haemoglobin on organ d is tribu tion  of 59pe was 
also assessed. Studies were also conducted after concomitant infusion 
of homologous tissue fe r r it in  together with the tagged HDRC.
2.11. Enhanced erythropoiesis
Er ythropoiesis was stimulated by removing 4 ml of blood via cardiac 
puncture under anaesthesia on the s ix th  and f i f t h  days p r io r  to 
commencement of the study. Enhanced erythropoiesis was confirmed by 
re ticu locy te  counting.
2.12. Free haemoglobin production
Free haemoglobin was produced by the method of Pippard and coworkers 
(1982). Blood removed from a donor ra t  was centrifuged at 2000 rpm for 
20 minutes, with the removal of plasma. To the resu lting  red c e lls  was 
added 4 times the volume of s te r ile  water. The resu lting  solution was 
centrifuged at 1000 rpm for 10 minutes to remove ce ll debris, and the 
resu lt ing  solution containing free haemoglobin was u tiliz e d .
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2 .13 . Homologous t i s s u e  f e r r i t i n
Homologous tissue fe r r it in  was produced by the method of Huebers and 
coworkers (1976). Donor ra ts  were anaesthetized, exsanguinated by 
cardiac puncture and washed out using normal saline perfusion. The 
l iv e r s  o f these  r a t s  were removed and su b je c te d  to  coarse  
homogenization in 4 times the ir volume of cold d is t i l le d  water. The 
homogenate was heated to 75-80°C in a waterbath with constant s t ir r in g . 
After heating for 10 minutes, the homogenate was cooled on ice and was 
centrifuged at 2000 rpm for 20 minutes. The resu lting  supernatant, 
with pH corrected to 4.9 by the addition of 25% acetic acid, was stored 
at 4°C for 12 hours, after which time i t  was again centrifuged at 2000
rpm for 20 minutes. To the resu lting  supernatant was added an equal
volume of saturated ammonium sulphate. After standing for a further 12 
hours at 4°C, the solution was centrifuged at 2000 rpm for 20 minutes. 
The resu lting  p e lle t was dissolved in the smallest volume of normal 
sa line and was dialysed against 2 l i t r e s  of normal saline for 36 hours. 
The normal sa line was changed every 12 hours during the 36 hour period.
After th is  time the dialysate was centrifuged for 10 minutes at 1000
rpm and the resu lt ing  supernatant was u t il iz e d  as the homologous tissue 
f  err i t i  n.
A lim u lus ly sa te  assay for endotoxin was performed by Sabax Ltd, 
Johannesburg on th is  tissue fe r r it in  preparation.
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2 .14 . S i z in g  column chromatography
H ep a tic  and s p le n ic  t is s u e  was p repared  fo r  s iz in g  column 
chromatography in  an attempt to characterize the nature of 59Fe, 
derived from prior in fusion of tagged HDRC, which was present in the RE 
c e lls  of the spleen and the RE and parenchymal c e lls  of the liv e r in 
the presence and absence of a highly saturated transferrin  and after 
prior transfusion with non-tagged HDRC. In an attempt to define the 
nature of iron released from RE c e lls ,  whole sera obtained after tagged 
HDRC infusion in to  animals with normal and saturated transferrins were 
also fractionated on AcA 44 column chromatography.
The buffer and column procedure were those of Pollack and coworkers 
(1985), namely an AcA 44 ultrogel column (LKB, Bromma, Sweden) and a 
0.05 M s a lin e ,  0.02 M hepes b u ffe r ,  pH 7.0. The precautionary 
procedure of bubbling nitrogen through the buffer to prevent iron- 
oxygen complexes from forming was employed as described (Pollack et a l , 
1985). The hydrophobic fe rrous che la to r 2 ,2 'b ip y r id in e  and the 
hydrophilic fe r r ic  chelator desferrioxamine were included in hepatic 
and sp lenic preparations to characterize the in tra ce llu la r chelatable 
pools of 59pe. At each time interval studied, a sample of live r and a 
sample of spleen was subjected to coarse homogenization in running 
buffer (0.05 M NaCl; 0.02 M Hepes; pH 7) containing soybean trypsin 
in h ib ito r  (100/jg/m l) and e ith e r desferrioxam ine (5 mg/ml) or 
2 ,2 'b ipyrid ine (1.39 mg/ml). The homogenized sample was centrifuged at 
1000 rpm for 10 minutes, after which time the resu lting  supernatant,
87
which contained near sing le c e ll suspensions, was sonicated with 3 
bursts of ultrasound of 30 seconds each at medium in tens ity  from an 
M.S.E. u ltrasonicator (Crawley, Sussex, U.K.). Post sonication the 
sample was subjected to u ltracentrifugation  at 25000 rpm for 40 minutes 
at 4°C. The resu lting  supernatant, a membrane and cytosol enriched 
sample, was fractionated on AcA 44 u ltro g e l chromatography. The 
fra c t io n s  c o lle c te d  were counted fo r r a d io a c t iv ity  in a Packard 
Autogamma s c in t i l la t io n  spectrometer model 5650. Prior to it s  use, the 
s iz in g  column was c a lib ra te d  w ith  ra d io la b e lle d  f e r r i t in  and 
tran sfe rrin . Between each sample application the column was washed 
with 12 ml 1% t r ito n  X-100 and 12 ml 0.1 M EDTA. At least 3 volumes of 
buffer were then run through the column prior to the next sample 
app lication .
Detergent so lub ilized  preparations of hepatic and splenic tissue were 
also subjected to s iz ing  chromatography on an AcA 44 ultrogel column. 
Coarse homogenization of sp lenic and hepatic tissue in running buffer 
containing soybean trypsin inh ib ito r but no chelators was followed by 
centrifugation of the homogenized samples at 1000 rpm for 10 minutes. 
Running buffer containing 2% tr ito n  X-100 was added to the resu lting  
p e lle t. After ag ita tion  at 4°C for 2 hours, the sample, representing a 
membrane enriched fraction , was subjected to u ltracen trifugation  at 
20000 rpm for 1 hour at 4°C. The supernatant was fractionated on an 
AcA 44 ultrogel chromatography column, and the fractions co llected were 
counted for rad io a c tiv ity  as before.
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The colours of the various fractions were also of use in confirming the 
nature of the peaks. The fe r r it in  peak (confirmed by quantitative 
immune prec ip ita tion) was brown in  colour and appeared at the void 
volume. This was followed by the haemoglobin peak which was red in 
colour. The small molecular weight desferrioxamine (brown) or 2,2' 
b ip y r id in e  (pink) peaks were the la s t  59pe containing fractions to 
elute from the column. Immune p rec ip ita tion  was by the methods of 
Morrow and co-workers (1986) and Enler and co-workers (1985) (see 
section 2.16. below).
2.15. In vivo chelator studies
These studies were conducted to confirm the fractionation  findings of 
the in vivo inclusion of chelators in  hepatic and splenic preparations. 
2 ,2 'b ipyrid ine and desferrioxamine were administered in  doses of 50 
ml /kg intramuscularly one hour, 3 hours, 5 hours, and 7 hours after the 
intravenous in jection  of tagged HDRC to normal ra ts  and ra ts whose 
transfe rrin  had been saturated with carbonyl iron. The hydrophilic 
e x t r a c e llu la r  f e r r ic  che la to r diethylenetriam ine penta-acetic acid 
(DTPA) was also used in  the in vivo studies. I t  was administered by 
the intravenous route. In between in jections the ra ts were kept in 
metabolic cages. At the end of 8 hours, the ra ts  were exsanguinated by 
cardiac puncture and were perfused with normal sa line. The percentage 
d is tr ibu tion  of 59pe in the l iv e r ,  spleen, blood, kidneys, marrow, and 
u rine  and faeces c o lle c te d  over the p e r io d  s in c e  c h e la to r  
administration began was determined as was done previously.
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2 .16 . Immune p r e c i p i t a t i o n
Immune p rec ip ita tion  was by the methods of Morrow and co-workers (1986) 
and Enler and co-workers (1985).
A solution containing 0.5 ml of sample in running buffer (0.02 M Hepes; 
0.05 M NaCl; pH 7), 0.5 ml 0.2 M EDTA, 0.2 ml ra t  fe r r it in  (2 mg/ml) 
and 0.5 ml Ig G solution was incubated for one hour at 37°C. PEG 
solution (12% PEG 6000 in  0.2 M EDTA; pH 8.5) was added to a fin a l 
concentration of 3%. The resu lt ing  solution was le f t  to stand overnight 
at 4°C. The fo llow ing day i t  was centrifuged for 20 minutes at 2000 
rpm. The p e lle t was washed with 3% PEG solution and was counted in a 
Packard Autogamma s c in t i l la t io n  spectrometer model 5650.
2.17. S ta t is t ic a l analyses
These were by means of Student t  tests. Bonferroni corrections were 
applied when mare than two groups were compared. When ana lys is  
variance was ap p lied , an F value was generated. The level of 




3 .1 .  Serum i r o n  and unsa tu ra ted  i r o n  b in d in g  c a p a c i t y  f o l lo w in g :
3.1.1. Carbonyl iron administration
The time dependent e ffe c t of the oral administration of carbonyl iron 
to ra ts  on SI and TIBC is  shown in figure 2. I t  can be seen that a 
single dose of 400 mg of carbonyl iron resu lted in  a transient increase 
in  the percentage saturation of transfe rrin . A second dose of 200 mg 
of carbonyl iron 24 hours later resu lted in  a more protracted elevation 
in  the percentage sa tu ra tion  o f tran s fe rr in . The fact that the 
percentage saturation of transferrin  never exceeded 100% when estimated 
e it h e r  p u re ly  co l or im etr i c a l l y  or by a com b ina tion  o f SI 
co lo rim etrica lly  and unsaturated iron binding capacity by rad io isotop ic 
assay indicated that the carbonyl iron was not causing super saturation 
of transfe rrin  with consequent c ircu la ting  free iron.
3.1.2. HDRC infusions
The time dependent e ffects of a single 3 ml /kg infusion of HDRC and 3 
repeated 6 ml/kg infusions of HDRC on the same iron re lated parameters 
are also indicated on figure 2. The single 3 ml /kg HDRC infusion was 
followed by a transient increase in  transfe rrin  saturation maximal at 3 
hours post in fusion. The f i r s t  of the repeated 6 ml/kg infusions was 
followed by a sim ilar increase in the transferrin  saturation. The 
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Figure 2. The time dependent e ffe c t on SI (shaded bar) and UIBC (open 
bar) o f 2 doses of carbonyl iron (top frame), a single 
in fusion of 3 ml/kg HDRC (middle frame) and 3 repeated 
infusions of 6 ml/kg HDRC (bottom frame).
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3.2 . A n a ly t ic a l  organ d is t r ib u t io n  o f 59pe HDRC in  various 
experimental settings
3.2.1. Two doses of carbonyl iron
The e ffe c t of two doses of carbonyl iron (24 hours apart) on the fate 
of tagged HDRC (3 ml/kg of a 20% haematocrit solution) administered 
four hours a fte r  the second dose of carbonyl iron is  shown as a 
function of time post in fusion of the c e lls  in  Table I. In the control 
group of animals, the rate of clearance of HDRC was rap id, with greater 
than 60% o f HDRC cleared by 30 minutes. The organ spec ific  59pe 
a c t iv ity  was greatest in the spleen early on. With the passage of time 
there was a progressive loss of rad io iron  from the spleen with a 
concomitant r is e  of 59Fe a c t iv ity  in the blood and marrow. Whether 
th is  was due to d irect transfer of iron from RE c e l ls  to marrow 
erythroid precursors could not be answered d ire c tly  from the control 
data.
In animals w ith  satu rated  t ra n s fe r r in s ,  the sp len ic  pattern of 
rad io iron  uptake and release was almost iden tica l to the control group 
of animals. By contrast though, the rad io iron  present in the blood and 
marrow was s ig n if ic a n t ly  reduced when compared to control animals, and 
there was a s ig n if ic a n t ly  increased amount of 59Fe present in the 
l iv e r .  This suggests that there is  a s ig n ific a n t pathway o f iron  
tran sp o rt from spleen to liv e r ,  p a rticu la rly  in the presence of a 
saturated transfe rrin .
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TABLE I COMPARISON OF THE FATE OF 59FE HDRC IN 3 EXPERIMENTAL SETTINGS
Time post Marrow Liver Spleen Blood
infusion 
(hours)
0.5 3.2 (0.1) 16.6 (0.9) 45.1 (9.7) 35.2 (10.5)
1.5 6.3 (0.7) 26.0 (1.8) 47.8 (3.5) 19.9 (3.0)
Control 4.0 16.4 (1.2) 22.9 (2.1) 37.8 (1.7) ;22.9 (1.7)a
8.0 26.7 (1.2) 29.0 (3.2) 29.3 (2.7) 13.4 (1.4)
24.0 26.9 (1.8) 14.6 (3.3) 33.9 (1.5) 24.7 (0.1)
0.5 3.8 (2.2) 19.7 (4.2) 30.1 (2.7) 46.5 (0.7)
Carbonyl 1.5 6.7 (0.8) 39.0 (2.2)a 40.9 (3.3) 11.1 (2.9)
iron 4.0 10.4 (1.3)c 44.0 (3.9)c 36.3 (2.5) 9.3 (2.4)
8.0 15.7 (1.2)c 48.1 (1.8)a 28.6 (1.9) 7.6 (0.7)c
24.0 14.7 (1.0)d 43.7 (4.3)d 33.2 (5.2) 8.6 (0.1)d
0.5 5.8 (1.0) 26.6 (6.8) 56.7 (2.8) 11.1 (4.9)
Heat damaged 1.5 7.0 (0.4) 25.6 (0.4) 63.6 (0.6)b 3.8 (0.2)
red c e lls 4.0 11.3 (3.0) 29.5 (2.2) 53.5 (5.4)a 11.3 (0.3)
8.0 18.0 (0.8) 21.6 (3.9) 52.2 (2.6)a 8.3 (0.6)
Note. 59pe HDRC (3 ml /kg) were infused in to  control ra ts , into animals 
in  which the transferrin  saturation had been maximally ra ised by 2 prior 
oral administrations of carbonyl iron and into ra ts  which had received a 
pretransfusion of heat damaged red c e lls  (6 ml/kg). Mean (+_ SEM) organ 
counts o f 59pe at  various times are expressed as percentages of 
recovered counts.
a S ta t is t ic a lly  d iffe ren t (p < 0.05) from the other two groups which 
are s ta t is t ic a l ly  sim ilar
b S ta t is t ic a lly  d iffe ren t from group given carbonyl iron (p < 0.05) 
c S ta t is t ic a lly  d iffe ren t from control group (p < 0.05) 
d F ir s t  2 groups d iffe ren t at 24 hours (p < 0.05)
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3 .2 .2 .  P r e t r a n s fu s io n  o f  HDRC
The e ffects  of an infusion of unlabelled HDRC (6ml/kg) 8 hours prior to 
the infusion of the regular dose of 59pe HDRC on the organ d istribu tion  
of 59fe are also shown in  Table I.
In contrast to the resu lts  obtained fo llow ing the administration of 
carbonyl iron where there was hold up of rad io iron  in  the l iv e r ,  
pretransfusion of HDRC was associated with a hold up of HDRC derived 
S^Fe in  the spleen and a consequent reduction of blood and marrow 
a c t iv ity .  The fact that less than 1.5% of recovered counts were 
present in  the kidney in d ica ted  tha t s ig n if ic a n t  in travascu la r 
haemolysis of the HDRC had not occurred. This finding of sp len ic  
retention of iron is  in keeping with the observation that follow ing 
HDRC in fusions, only the f i r s t  in fusion of HDRC was associated with a 
r i s e  in  t ra n s fe r r in  saturation . The lack of r is e  in transferrin  
saturation fo llow ing subsequent infusions of HDRC is  due to the fact 
that the RES is  conditioned by the f i r s t  load of HDRC to store iron 
rather than release i t  into the c ircu la t ion .
3.2.3. Single dose of carbonyl iron
That the altered organ d is tribu tion  was not a function of a protracted 
(>24 hours) increased transferrin  saturation was demonstrated when 
tagged HDRC were infused into ra ts  1 hour after the f i r s t  feeding of 
oral carbonyl iron and the animals were sa c rificed  four hours la ter.
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The organ d is tr ibu tion  was sim ilar to that noted when a high percentage 
saturation was maintained for greater than 24 hours with two doses of 
carbonyl iron, namely reduced marrow and blood 59Fe with a strik ing  
increase in hepatic 59pe a c t iv ity  (Table II) .
3.2.4. Enhanced erythropoiesis
In the next s e r ie s  o f experim en ts the e f f e c t  o f enhanced 
e ry th ro p o ie s is ,  induced by p r io r  venesection, on the 59pe organ 
d is tr ibu tion  4 hours after the infusion of tagged HDRC was assessed. 
The enhanced erythropoiesis was confirmed by c ircu la t in g  re ticu locy te  
counts in the region of 20% compared to controls of less than 2%. The 
e ffe c t of the increased erythropoiesis was to markedly increase 59Fe 
counts in the blood and marrow. This was at the expense of the spleen 
predominantly, the 59pe content of which was s tr ik in g ly  reduced. The 
59Fe content of the liv e r  was l i t t l e  changed (Table I I I ) .  The e ffect 
of th is  enhanced e ry th ro p o ie t ic  ra te  was n u l l i f ie d  by the ora l 
a dm in is tra t ion  o f the 2 doses o f carbonyl iron. In the la tter 
experiments, although the re ticu locy te  count was again increased to the 
level of approximately 20%, transfe rrin  saturation was increased to the 
region of 90-95% by the 2 doses of carbonyl iron. This resulted in the 
organ d is t r ib u t io n  o f 59pe not  being s ig n ific a n t ly  d iffe ren t from 
animals w ith  normal e ry th r o p o ie s is  and enhanced t r a n s f e r r in  
sa tu ra t io n s . These experiments were terminated at 4 hours post 
infusion of tagged HDRC.
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TABLE II THE FATE OF 59FE HDRC 4 HOURS AFTER THEIR INFUSION INTO 
CONTROL ANIMALS AND ANIMALS WHOSE TRANSFERRIN SATURATION WAS 
TRANSIENTLY ELEVATED BY THE ORAL ADMINISTRATION OF CARBONYL IRON ONE 
HOUR PRIOR TO HDRC INFUSION.
Marrow Spleen Liver Blood




5.9 (0.7) 28.1 (4.6) 59.8 (3.8) 6.2 (0.1)
t  value 5.2555 2.5469 9.0742 9.6970
p value <0.0005 <0.0314 <0.0001 <0.0001
Note: Results are shown as means (SEM) of percentage recovered counts 
by organs
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TABLE III COMPARISON OF THE FATE OF 59FE HDRC INFUSED INTO CONTROL RATS 
AND ANIMALS WITH ENHANCED ERYTHROPOIESIS
Marrow Liver Spleen Blood
Control 16.4 (1 .2 ) 22.9 (2 .1 ) 37.8 (1 .7) 22.9 (1 .7 )
Control plus
carbonyl iron 10.4 (1 .3 ) 44.0  (3 .9) 36.3 (2 .5) 9.3 (2 .4 )
Venesection 27.3 ( l . l ) a 18.6 ( 6 . 8 ) c 23.8 ( 3 . 0 ) a 30.4 ( 2 . 7 ) b
Venesection plus
carbonyl iron 11.4 ( 1 . 8 ) c 44.6 ( 1 . 9 ) c 34.2 ( 3 . 6 ) c 10.0 ( 0 . 2 ) c
Note. 59Fe labe lled  heat damaged red c e lls  were infused into control 
ra ts  and in to  animals which had been venesected of 4 ml blood 6 and 5 
days prior to the study. A further control and venesected group were 
fed two prior doses of oral carbonyl iron to increase the percentage 
saturation of transfe rrin . Mean (+_ SEM) 59Fe organ counts are expressed 
as percentages of recovered counts at 4 hours after the infusion.
a S ign ifican tly  d iffe ren t from the control group (p < 0.01) 
b Not s ig n if ic a n t ly  d iffe ren t from the control group (p < 0.08) 
c Not s ig n if ic a n t ly  d iffe ren t from the appropriate control group.
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3 . 2 . 5 .  P r i o r  c a rb o n y l  i r o n ,  p r e t r a n s fu s io n  w ith  untagged HDRC, a
combination of both, and prior carbonyl iron plus free haemoglobin 
infusion 8 hours after 59Fe HDRC in jection
In an attempt to further define the pathways in  internal iron exchange, 
the organ d is tr ibu tion  of 59Fe HDRC at 8 hour was tested in several 
groups of 3 animals each. The groups included a control group, one 
which had received prior carbonyl iron, one which had received prior 
unlabelled HDRC, one which had received both and one which had received 
prior carbonyl iron and unlabelled free hemoglobin (Table IV). The 
prior administration of both carbonyl iron and unlabelled HDRC was 
associated with splenic retention, which is  the pattern obtained in  a 
previous experiment when HDRC were given alone (Table I). In contrast, 
when p r io r  carbonyl iro n  and free  haemoglobin were administered 
together, the pattern of increased hepatic counts was sim ilar to that 
obtained with carbonyl iron alone. Marrow and blood a c t iv ity  were 
reduced by a l l  the manoeuvres and the adm in is tra tion  o f fre e  
haemoglobin was associated with an increase in kidney counts.
3.3. S izing column chromatography
3.3.1. Introduction
In an attempt to understand the e ffects of a saturated transferrin  and 
prior transfusion on re ticu loendothe lia l and parenchymal c e l l  iron  
processing  from HDRC, sp len ic and hepatic cy toso lic  extracts were
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TABLE IV THE EFFECTS OF PRIOR CARBONYL IRON, PRETRANSFUSION WITH 
UNLABELLED HDRC, A COMBINATION OF BOTH, AND PRIOR ORAL CARBONYL IRON 
PLUS AN INFUSION OF FREE HAEMOGLOBIN ON THE ORGAN DISTRIBUTION OF 59FE 8 
HOURS AFTER THE INJECTION OF 59FE LABELLED HEAT DAMAGED RED CELLS.
Marrow Spleen Liver Blood Kidney
Control 35.4 (3.9)d 20.6 (2.3) 35.0 (5.0)b 9.0 (0.2)a 2.2 (0.7)
Carbonyl
iron
18.0 (0.6) 23.5 (1.0) 52.1 (0.7) 6.4 (0.7) 2.9 (1.4)













20.7 (1.4) 20.6 (1.0) 54.4 (2.1) 4.3 (0.5) 5.5 (0.2)
Note. Mean (+ SEM) organ counts of 9^Fe 8 hours after the in jection  are 
expressed as percentages of recovered counts
a S ta t is t ic a lly  d iffe ren t from the other groups which are 
s ta t is t ic a l ly  equivalent (F = 34.9; p < O.OOOl) 
b S ta t is t ic a lly  sim ilar but d iffe ren t from the other groups 
(F = 12.7; p < 0.006)
c S ta t is t ic a lly  sim ilar but d iffe ren t from the other groups which 
were sim ilar (F = 24.0; p < 0.0006) 
d S ta t is t ic a lly  d iffe ren t from the other groups which were 
s ta t is t ic a l ly  equivalent (F = 61.7; p < 0.0001)
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subm itted to s iz in g  chromatographic an a ly s is  on AcA 44 ultrogel 
chromatography. The nature of the 59pe peaks obtained o ff the column 
was id e n t if ie d  by comparison to ca lib ra tion  with known iron transport 
and storage proteins, by immune p rec ip ita tion  and by u t il iz a t io n  of the 
characte ris tic  colours of fe r r it in ,  haemoglobin, ferrioxamine and the 
2,2' b ipyrid ine-iron  complex. The re la t iv e  sizes of these peaks were 
calcu lated as a percentage of the counts recovered from the column. The 
2,2' b ipyrid ine-iron  peak was of s lig h t ly  lower molecular size (sh ifted 
to the r ig h t  of) than the ferrioxam ine peak. R ep resen ta tive  
chromatograms for sp lenic and hepatic cy toso lic  preparations and for 
hepatic detergent extracted membrane enriched fractions compared to 
ca lib ra tion  of the column, are shown in figure 3.
3.3.2. Time dependent fractionation  of splenic extracts
The re su lts  of the time dependent an a ly s is  o f sp le n ic  c y to so lic  
preparations in terms of 9^Fe from HDRC as a function of a normal 
transfe rrin , a saturated transfe rrin  or prior transfusion are shown in 
Table V. In a l l  groups there was a progressive s h if t  of 59pe from the 
haemoglobin pool in to  the fe r r it in  pool with a re la t iv e ly  consistent 
small m olecular weight component. Overa ll there were no major 
differences between groups in the percentage d is tribu tion  of the iron 
peaks. The c la im  tha t the con tro l group was one with a normal 
transferrin  saturation is  somewhat of an o v e rs im p lif ic a t io n  since 
infusion of the HDRC per se did produce an increase of transferrin  
saturation as the iron (roughly 0.8 mg/kg) from these red c e lls  was
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Ferritin Calibration
Figure 3. Representative chromatograms for splenic (second frame) 
and hepatic (th ird  frame) cytoso lic  preparations and for 
hepatic detergent extracted membrane enriched fraction  
(bottom frame), compared to ca lib ra tion  of the column 
with fe r r it in  and transferrin  (top frame).
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TABLE  V T IM E  DEPENDENT FR A C T IO N A T IO N  OF S P L E N IC  EXTRACTS
Time F e r r i t i n
pos t  i n f u s i o n  
(min)
Haemoglobi n
Small  mo le cu la r  we igh t  
F e r r i c  Fe r rous
Contro l 1.6 (0.5) 88.1 (0.5) 6.0 (0.2) -
Carbonyl i r o n 30 1.9 (0.2) 86.9 (0.9) 4.0 (0.4) -
Heat damaged red c e l l s 4.0 (1.3) 87 .9 (2.3) 6.1 - 2.4 (0.1)
Cont ro l 9.9 (1.1) 80.7 (1.3) 5.7 (1.5) 2.7 (0.2)
Carbonyl  i r o n 90 11.9 (0.4) 75.0 ( 1 . 4 ) a 8.5 (0.7) 7.6 (2.1)
Heat damaged red ce l 1 s 12.5 (1.3) 79.7 (1.2) 3.7 (0.1) 2.3 (0.2)
Cont ro l 19.2 ( 2 . 8 ) b 62.7 (3.6) 4.8 (0.3) 5.2 (0.2)
Carbonyl  i r o n 240 37.2 (3.3) 51.4 (3.1) 5.6 (0.8) 3.6 (0.4)
Heat damaged red c e l 1 s 42.0 (2.4) 51.4 (3.0) 3.4 (0.3) 2.1 (0.2)
Cont ro l 73.8 (3.7) 18.5 (3.5) 3.6 (0.3
Carbonyl i r o n 480 86.0 (1.9) 9.5 (1.5) 2.5 (0.1) -
Heat damaged red c e l l s 72.7 (0.9) 22.7 (1.2) 2.4 (1.5) 2.2 (0.9)
Note. S p l en i c  t i s s u e  was f r a c t i o n a t e d  i n t o  f e r r i t i n ,  haemoglobin and smal l  m o l e cu l a r  we igh t  
peaks a f t e r  the g i v i n g  o f  59Fe l a b e l l e d  HDRC. The groups i n c l u d e  c o n t r o l  r a t s ,  an ima l s  
which had r e c e i v ed  p r i o r  o r a l  carbo/iv l i r o n  and those whi ch had r e c e i ved  p r i o r  u n l a b e l l e d  
HDRC. Mean (+ SEM) organ counts  o f  59Fe a t v a r i o u s  t imes are expressed as pe rcentages  of  
recovered  counts .  S t a t i s t i c a l  compar i sons  r e f e r  on l y  to f e r r i t i n  and hemoglobin as the 
smal l  m o l e cu l a r  we igh t  c h a r a c t e r i s a t i o n s  were per formed on on ly  smal l  numbers o f  samples.
a
b
S t a t i s t i c a l l y  d i f f e r e n t  from co n t r o l  group (p < 0.05)
S t a t i s t i c a l l y  d i f f e r e n t  from ca rbony l  i r o n  and heat  damaged red c e l l  groups 
(p < 0.05)
processed ( f i gu re  2). C lea r l y  t h i s  may have led to a somewhat 
exaggerated f e r r i t i n  peak on c y to so l i c  59Fe analysis of splenic 
material in the a llegedly normal saturation animals.
3.3.3. Time dependent fractionation  of hepatic extracts
Time dependent hepatic cy toso lic  59pe analysis post HDRC infusion in 
animals o f normal t r a n s f e r r i n  sa tu ra t io n , increased t r an s fe r r i n  
saturation and prior infusion of HDRC are shown in  Table VI. There 
were s tr ik in g  differences between splenic fractionation  (Table V) and 
hepatic f r a c t io n a t io n .  At the times studied the liv e r contained 
s tr ik in g ly  less haemoglobin 59Fe but more fe r r it in  and small molecular 
weight 59Fe than d id  the sp leen. The carbonyl i ron group had 
s ig n if ic a n t ly  more hepatic small m olecular weight i ron,  (both in 
percentage and absolute terms) than the normal or pretransfusion groups 
while 59pe fe r r it in  was increased in  both the carbonyl iron and prior 
transfused groups.
3.3.4. Fractionation of so lub ilized  c e ll and membrane pe lle ts
In an attempt to investigate the ce llu la r  level at which the saturated 
transferrin  was exerting it s  e ffe c t, detergent so lub ilized  extracts of 
hepatic and splenic c e ll and membrane p e lle ts  obtained 90 minutes after 
HDRC in f us ions  i nto  con tro l animals and animal wi th saturated 
transferrins were fractionated for 59pe a c t iv ity  on AcA 44 ultrogel 
s iz ing  column chromatography (Table VII). These detergent extracts
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TABLE  VI T IM E  DEPENDENT FR A C T IO N A T IO N  OF H E P A T IC  EXTRACTS
Small  m o l e cu l a r  we igh t
Time F e r r i t i n Haemoglobi  n F e r r i c Fer rous
Cont ro l
pos t  i n f u s i o n  
(min)
5.0 (0.6 )a 61.9 ( 3.5 )6 17.3 (2.4) 17.9 (0.9)
Carbonyl  i r o n 90 20.0 (1.9 ) a 42.2 (3.3) 28.3 (4.8) 24.9 (0.9)
Heat damaged red c e l l s 36.3 ( 1 . 8 ) a 38.8 (2.0) 15.9 (0.3) 16.0
Contro l 47 .4 (2.7) 17.8 (3.6) 18.5 (5.6) 20.8 (3.7)
Carbonyl  i r o n 240 51.4 (7.1) 10.8 (1.5) 22.0 (9.6) 28.4 (11.9)
Heat damaged red c e l l s 81.2 ( 8.2 )c 7.1 (3.0) 6.9 4.3
Note. Hepa t i c  t i s s u e  was f r a c t i o n a t e d  i n t o  f e r r i t i n ,  haemoglobin and smal l  m o l e cu l a r  we igh t  
peaks a f t e r  the g i v i n g  o f  9^Fe l a b e l l e d  HDRC. The groups i n c l u d e  c o n t r o l  r a t s ,  an ima l s  
which had re c e i v ed  p r i o r  o ra l  carbony l  i r o n  and those which had r e c e i ved  p r i o r  u n l a b e l l e d  
heat damaged red c e l l s .  Mean ( + SEM) organ counts  o f  5®Fe a t v a r i o u s  t imes  are expressed 
as pe rcentages  o f  recovered  counts .  S t a t i s t i c a l  compar i sons r e f e r  on ly  to f e r r i t i n  and 
hemoglobin peaks as the smal l  m o l e cu l a r  we i gh t  compar i sons  were per formed on smal l  numbers 
of  samples.
a Each s t a t i s t i c a l l y  d i f f e r e n t  from the o t he r  2 groups (p < 0.05)
b S t a t i s t i c a l l y  d i f f e r e n t  from the o the r  2 groups (p < 0.05)
S t a t i s t i c a l l y  d i f f e r e n t  from co n t r o l  group (p < 0.05)c
TABLE V II  FRACTIONATION OF SOLUBILIZED CELL AND MEMBRANE PELLETS
High molecular Mid-range Haemoglobin 
weight peak 59Fe a c t iv ity  peak
Control 32.4 (3.6) 29.6 (2.7) 27.4 (4.6)
Li ver
Carbonyl iron 45.9 (1.5) 19.0 (4.9) 26.5 (2.7)
Control 13.6 (1.5) 10.8 (3.6) 69.0 (7.2)
Spleen
Carbonyl iron 19.1 (2.0) 13.8 (3.1) 61.9 (2.9)
Note. The mean (+ SEM) percentage d is tr ibu tion  of 59Fe hepatic and 
splenic a c t iv ity  in so lub ilized  c e ll and membrane pe lle ts  90 minutes 
a fte r  the adm in is tra tion  of 59pe labe lled  HDRC in controls and in 
animals which had received prior oral carbonyl iron. The pe lle ts  were 
s o l u b i l i z e d  with tr ito n  and fractionated on an AcA ultrogel sizing 
column.
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revealed 3 regions of 59pe a c t iv ity , namely a high molecular weight 
(void) fraction , a haemoglobin fraction  and a midrange fraction  between 
these two peaks. No s ta t is t ic a l ly  s ig n ific an t differences were noted 
between the tota l 59Fe a c t iv ity  in the p e lle ts  (not shown in table) or 
in the d is tribu tion  between the r ad i o i r on  peaks, in cont ro l s  as 
compared with animals in which the transferrin  saturation had been 
ra ised by prior administration of carbonyl iron.
3.4. Parenteral adm inistration of chelators
In an attempt to further e lucidate the spleen to l iv e r  cyc le of 
rad io iron , the e ffe c t of various chelators on the organ d is tribu tion  of 
59Fe 8 hours after the infusion of labe lled  HDRC into control animals 
and animals with increased transferrin  saturations was studied. The 
chelators employed were desferrioxamine, an in tra ce llu la r hydrophilic 
fe r r ic  chelator, DTPA, an extrace llu la r hydrophilic fe r r ic  chelator and 
2,2' b ipyrid ine, a membrane hydrophobic ferrous chelator.
The e f f e c t s  o f the p a re n te ra lly  adm in istered che la to rs  on the 
d is tr ibu tion  of 59Fe HDRC are shown in Table VIII.  In the control 
animals a l l 3 chelators caused a modest but s ta t is t ic a l ly  in s ign ifican t 
reduction in the 59Fe hepatic pool. In control animals given carbonyl 
iron the size of the hepatic pool was increased and the che lators 
caused a s i g n i f i c a n t  reduct ion in i t s  s i ze .  Marrow uptake was 
s ig n if ic a n t ly  decreased by 2,2' bi pyridine in the control group and 
there was a concomitant increase in blood a c t iv ity . A s im ila r, though
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TABLE V I I I THE EFFECT OF VARIOUS CHELATORS ON THE DISTRIBUTION OF 59FE IN ORGANS
Che l a t o r Marrow L i v e r Spleen Blood Non-recovered
None 20.0 (2.3) 20.8 (3.6) 24.3 (3.4) 9.7 (1.7) 25.3 (2.7)
Cont ro l 2 ,2 '  b i p y r i d i n e 5.7 (0.4 )b 15.1 (1.7) 15.6 (0.3) 22.3 ( 3 . 4 ) b 41.4 (3.5)
D e s f e r r i  oxami ne 20.8 (2.2) 14.6 (1.7) 22.0 (0.5) 10.7 (1.1) 31.6 (4.1)
DTPA 14.0 (3.2) 17.4 (2.0) 14.5 ( 2 . 0 ) b 9.8 (1.3) 43.3 (8.3)
P r i o r None 13.3 (3.4) 34.0 (3.5) 18.2 (1.1) 6.4 (0.2) 28.2 (3.9)
carbony l 2 ,2 '  b i p y r i d i n e 6.4 (2.0) 16.9 ( 0 . 3 ) a 18.2 (0.9) 19.0 ( l . l ) b 39.6 (0.4)
i ron O e s f e r r i  oxamine 9.8 (0.2) 17.4 { 0.2 ) a 20.2 (0.5) 5.8 (1.2) 46.9 (1 • 7 )b
DTPA 7.5 (0.5) 21.0 { 3.8)  a 14.8 (3.3) 7.3 (1.0) 49.5 ( 0 . 0 ) b
Note. The e f f e c t  o f  v a r i o u s  c h e l a t o r s on the 8 hour organ di  s t r i  bu t i on o f  59 Fe 1a b e l 1ed HDRC i n
c o n t r o l  r a t s  and in  an ima l s  which had r e c e i v ed  p r i o r  o ra l  ca rbony l  i r o n .  The c h e l a t o r s  were 
adm in i s t e r e d  p a r e n t e r a l l y  s t a r t i n g  1 hour a f t e r  the i n f u s i o n  o f  the red c e l l s .  Mean (+ SEM) organ 
counts  are expressed as pe rcen tages o f  recovered  counts .
a A l l  three  s t a t i s t i c a l l y  e q u i v a l e n t  but  t oge t he r  s i g n i f i c a n t l y  d i f f e r e n t  from l i v e r  counts i n  the 
carbony l  group which d id  not  r e c e i v e  any c h e l a t o r s  ( f  = 23.5; p < 0.005) 
b S i g n i f i c a n t l y  d i f f e r e n t  from the a p p r o p r i a t e  group which d id  not  r e c e i v e  any c h e l a t o r  (p < 0.05)
less marked trend was noted in the carbonyl group. DTPA s ig n ifican tly  
reduced the splenic pool in the control group and a sim ilar but not 
s ig n if ic a n t reduction was noted in  the animals given prior carbonyl 
iron.
3.5. Fractionation of serum
Serum obtained 30 minutes after the administration of the 59pe HDRC was 
fractionated on AcA 44 u ltrogel chromatography. Organ d is tribu tion  in 
the control and carbonyl iron groups was sim ilar. The transferrin  
saturations were 51.0 (SEM 1.5)% and 91.3 (SEM 5.5)% respectively. In 
the serum of the control animals there was an equal d is tribu tion  of 
rad io iron  between fe r r it in  and transfe rrin , while in the animals which 
had received carbonyl iron the transferrin  peak was very small (Figure 
4).
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Figure 4. Fractionation on an AcA 44 ultogel column of equal volumes 
of whole serum 30 min post 59pe HDRC infusion in normal ra ts 
(middle frame) and in rats given prior oral carbonyl iron 
(bottom frame). Calibration of the column for fe r r it in ,  




4.1. The e ffe c t of a saturated transferrin
In the current investigation the enteral administration of carbonyl 
iro n  proved to be an e f fe c t iv e  way o f producing an increased 
transferrin  saturation without the r is k  of supe rsa tu ra tion . This 
manoeuvre was used as the method fo r eva lua ting  the e f fe c t  of 
transfe rrin  saturation on the regulation of the internal exchange of 
erythrocyte derived iron.
The re su lts  of previous work have shown that saturation of transferrin  
w ith iron  causes a marked reduction  in  iron  re lease  from the 
reticu loendothe lia l system (L ipsch itz et a l , 1971c; Bergamaschi et a l , 
1986). In the present study re su lts  were somewhat d iffe ren t, possibly 
due to the fact that transferrin  saturation was produced in a more 
physiological way. Whereas both acute and more sustained increases in 
transfe rrin  saturation had no e ffe c t on the splenic retention of iron 
derived from HDRC, an increase in hepatic retention of iron was noted.
The heat damaged red c e ll in fusion did per se re su lt in a transient 
increase in transferrin  saturation which may to a degree have modified 
the pattern of internal iron exchange in animals with the so ca lled  
control transferrin  saturation. Splenic retention of rad io iron  was 
however enhanced by the prior infusion of unlabelled HDRC. This la tter 
observation was supported by another experiment in which the percentage 
saturation of transferrin  was measured after repeated in jections of
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HDRC. Only the f i r s t  infusion was associated with a r is e  in the 
t ra n s fe r r in  sa tu ra t io n . The lack  o f any subsequent r is e s  was 
presumably due to a conditioning of the reticu loendothe lia l c e lls  by 
the f i r s t  load of HDRC to store the released iron rather that to 
deliver i t  back to the plasma.
Stimulation of erythropoiesis by venesection in animals that had not 
received carbonyl iron caused a m obilization of iron from both live r 
and spleen and i t s  tra n s fe r to red  c e l l  precursors. Saturating 
transferrin  by the prior administration of carbonyl iron prevented th is  
enhanced ce llu la r  iron release despite the increased erythropoietic 
acti vi ty .
4.2. The nature of iron transport from the spleen to the liv e r
An attempt was made to explain the nature of the iron transport from 
sp leen  to l iv e r ,  p a r t ic u la r ly  in  the presence o f a saturated 
transfe rrin . Prior infusion of an equivalent amount of haemoglobin as 
free haemoglobin did not a lte r the red is tr ibu tion  of 59Fe from spleen 
to liv e r in carbonyl treated ra ts . This argues strongly against th is  
c i r c u i t  be ing  a h ap tog lob in -h aem og lob in  one consequent upon 
intravascular haemolysis in the spleen (Bergamaschi et a l , 1986). I f  
the haptoglobin-haemoglobin pathway was the explanation i t  s t i l l  would 
not explain why intravascular haemolysis should be increased in the 
setting of the increased transfe rrin  saturation and why the major hold-
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up should s t i l l  not be in  the spleen i f  haemolytic ra te s  were 
equivalent.
The splenic and hepatic fractionation  studies gave a further clue as to 
the nature of the splenic-hepatic c ir c u it .  The fractionation  studies 
showed that while in both organs there was a progressive s h if t  of 59Fe 
from haemoglobin in to  fe r r it in ,  possibly through a small molecular 
weight chelatable pool, at any given time the haemoglobin fraction  in 
the liv e r was s ig n if ic a n t ly  smaller than that in  the sp leen. By 
contrast the small molecular weight and fe r r it in  peaks were much larger 
at any given time in the liv e r .  The question then is  whether the 
nature of the 59pe transport was as fe r r it in  or some small molecular 
weight non-transferrin bound form of iron.
In th is  regard recent work has shown that iso la ted  macrophages release 
iron in the form of fe r r it in  (S ib il le  et a l , 1988) and that th is  
fe r r it in  is  rap id ly  taken up by iso lated  hepatocytes (S ib il le  et a l , 
1988) presumably by a receptor mediated pathway (Mack et a l , 1983). 
Non-transferrin iron has also been shown to be very e ffe c tive ly  taken 
up by hepatocytes (Wright et a l , 1988). The fractionation studies 
in d ic a te ,  in  abso lu te terms, that in the presence of a saturated 
transfe rrin , at 90 minutes, 8% of recovered counts were present in 
fe r r i t in  and roughly 10% in the small molecular weight pool in the 
liv e r .  This compares to roughly 1% and 4.5% in the control animals. 
By 240 minutes these values were 22.5% and roughly 11% in  the saturated
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transfe rrin  group while the control group had values of 11% and roughly 
4.5%.
To further evaluate whether the 59pe transport from spleen to liv e r was 
as fe r r it in  or as some small molecular weight non-transferrin bound 
form o f iro n , in je c t io n s  of homologous r a t  tissue fe r r it in  were 
administered an hour prior to and 2 hours post HDRC administration. 
Organ d is tr ibu tion  of 59pe was assessed at 8 hours post HDRC infusion. 
The re su lts  showed that both control and saturated transferrin  groups 
of animals exhibited marked splenic 59pe retention with l i t t l e  59Fe 
being released into the blood and transported to the l iv e r .  The 
explanation for th is  re la ted  to consistently high t it re s  of endotoxin 
being detected on limulus lysate assay of the homologous ra t  tissue 
fe r r it in  preparation. Endotoxin i t s e l f  causes major perturbations of 
internal iron transport (Torrance et a l , 1978).
Whole serum fractionation  studies at 30 minutes post HDRC infusion 
showed that there was no increase in the c ircu la ting  fe r r it in  59Fe peak 
in the animals with saturated transfe rrin . Since th is  was evaluated in 
systemic blood rather than portal blood the p o ss ib ility  s t i l l  exists 
that enhanced hepatic fe r r it in  clearance might have lim ited a r is e  in 
the c ircu la t in g  fe r r it in  peak. The existence of such a c ircu la ting  
59Fe f e r r i t i n  peak a fte r  HDRC in fu s io n  has previously been well 
documented (Siimes and Dallman, 1974). In the animals with a saturated 
t ra n s fe r r in  whole serum fractionation  indicated an absence of the 
transfe rrin  59pe peak.
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The study involving various classes of chelators shed some further 
lig h t  on possible iron release mechanisms and the nature of the spleen 
to liv e r iron pathway. In animals with normal transferrin  saturations, 
the ex trace llu la r hydrophilic chelator DTPA markedly enhanced splenic 
iron release. Th is, together with the studies on animals with enhanced 
erythropoiesis, suggests that re ticu loendothe lia l iron release can be 
enhanced by increased unsaturated iron binding capacity. The finding 
tha t in  con tro l an im als, the membranous fe rrous che la tor 2,2' 
b ipyrid ine was associated with an increased amount of 59pe -jn the blood 
and reduced 59pe j n the marrow is  compatible with the observation that 
2,2' b ipyrid ine decreases iron uptake from d ife r r ic  transferrin  by a 
number of c e ll types, including erythroid precursors (Morgan, 1983; 
Nunez et a l , 1983; Baynes et a l , 1988a; 1988b). The increased
hepatic retention of iron derived from 59pe labe lled  HDRC noted in 
animals with saturated transferrins was reduced by a l l  three chelators. 
Each, however, must have obtained it s  iron from a d iffe ren t pool. 2,2' 
b ipyrid ine presumably removed ferrous iron from splenic or hepatic 
c e llu la r  membranes or both, DTPA obtained fe r r ic  iron released by the 
spleen, while desferrioxamine procured it s  iron from a fe r r ic  pool 
predominantly in hepatocytes (Pippard et a l,  1982).
There was one further point of in te rest. Fractionation of so lub ilized  
membrane enriched fractions from spleens and liv e rs  after the infusion 
of 59Fe HDRC did not show any accumulation of rad io iron a c t iv ity  in the 
hepatic membranes of animals with a saturated t ra n s fe r r in .  Th is
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find ing suggests that membrane transport is  not a rate lim it ing  step in 
iron release from the liv e r .
4.3. The small molecular weight la b ile  iron pool
The findings of th is  study have contributed to the knowledge of the 
nature of the small molecular weight la b ile  iron pool. The cytoso lic 
fractionation  studies confirmed that the iron in th is  pool appears to 
be of a low molecular weight and illu s tra te d  that the iron in th is  pool 
is  made up of both ferrous and fe r r ic  components. Enlargement of th is  
pool fo llo w in g  the infusion of HDRC into animals with a saturated 
transferrin  appears to be a transient phenomenon, as evidenced by the 
find ing that with the passage of time, less iron was present in th is 
form and more was present in the form of fe r r it in .  The transient 
nature of th is  pool has been documented by others (Young et a l,  1985; 
Bomford et a l , 1986).
There are in v itro  and in vivo data to suggest that enlargement of the 
in t r a c e l lu la r  small m olecular weight iron  pool is  a tran s ien t 
phenomenon because th is  iron induces a red is tr ibu tion  of cytoso lic 
fe r r it in  mRNA from being free w ithin the cytosol to being attached to 
polyribosomes (Aziz and Munro, 1986; Rogers and Munro, 1987). This 
resu lts  in enhanced fe r r it in  mRNA translation  and in increased fe r r it in  
synthesis, which in turn would tend to reduce free low molecular weight 
iron by incorporating th is  iron into the newly synthesized fe r r it in .
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The f in d in g  in  th is  investigation of an increase in in tra ce llu la r 
fe r r it in  59Fe content soon after the infusion of HDRC into animals with 
saturated transferrins is  in keeping with the observation that new 
f e r r i t i n  production is  mediated at a translationa l level in iron 
storage c e lls  (Aziz and Munro, 1986). The red is tr ibu tion  of fe r r it in  
mRNA has re c e n t ly  been demonstrated to be mediated by an iron 
responsive element on the fe r r it in  mRNA which e ffects the s h if t  of the 
cytoplasmic fe r r it in  mRNA to the polyribosomes (Aziz and Munro, 1986; 
Rogers and Munro, 1987; Hentze et a l , 1987; Leibold and Munro, 1988; 
Casey et a l , 1988; Dickey et a l , 1988).
4.4. Implications of th is  investigation
The findings of th is  investigation can be seen as further evidence of 
the important ro le  that non-transferrin iron has to play in internal 
iron exchange, especia lly  in conditions of a saturated transferrin .
The documentation by others (Hershko et a l , 1978; Anuwatanakulchai et 
a l , 1984; Gutteridge et al,1985; Wang et a l , 1986) of the presence of 
much higher concentrations of tota l iron c ircu la t in g  in the form of low 
molecular weight complexes not bound to transferrin  in the plasma of 
patients with severe iron overload, together with the documentation of 
the highly e f f ic ie n t  hepatic clearance of th is  form of iron (Brissot et 
a l , 1985) have highlighted the importance of th is  form of iron in the 
hepatic iron loading and to x ic ity  that characterizes many of the iron 
load ing  sta tes. In the current investigation, the resu lts  of the
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fra c t io n a t io n  studies of hepatic extracts from control animals and 
those with saturated transferrins suggest tha t d iffe ren ce s  in  the 
amount of iron present in the form of low molecular weight complexes 
are contributing to the altered organ d is tribu tion  of iron derived from 
HDRC. These resu lts  also serve to confirm and emphasize the central 
ro le  that the low molecular weight complexes are p lay ing  in  the 
ae tio lo gy  o f hepatic iron  load ing, especia lly  in conditions of a 
saturated transfe rrin .
While i t  is  known that fe r r it in  is  rap id ly  cleared from the c ircu la tion  
by hepatocytes, probably by a receptor mediated process (Mack et 
al,1983; Morgan and Baker, 1986), what proportion of non-transferrin 
iron fe r r it in  constitutes and the ro le  i t  may play in hepatic iron 
load ing  is  s t i l l  not c lear. Recently i t  has been suggested that 
fe r r it in  may serve as an intrahepatic carrie r of iron between Kupffer 
c e lls  and hepatocytes (Kondo et al,1988; S ib i l le  et a l , 1988) and that 
th is  may explain the su scep t ib ility  of the liv e r to iron overload.
While serum fractionation  studies performed in th is  investigation were 
unable to show an increase in c ircu la ting  fe r r it in  in animals with 
saturated transfe rrin s, th is  was evaluated in systemic blood rather 
than portal blood. The p o s s ib ility  ex ists that fe r r it in  may be playing 
an important part in iron transport from the spleen to the liv e r in 
conditions of a saturated transferrin  and may be partly responsible for 
hepatic iron loading. Enhanced hepatic fe r r it in  clearance may lim it  a 
r is e  in c ircu la t in g  f e r r i t i n  le v e ls ,  but fra c t io n a t io n  o f serum
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obtained from the po rta l vein by i t s  cannu lation  may shed more 
information on the ro le  that fe r r it in  has to play in iron transport 
from the spleen to the liv e r .
4.5. A model of internal iron exchange
Based on the resu lts  of the investigations carried out in th is  study, a 
model to exp la in  the regu lation  of the internal exchange of HDRC 
derived iron was arrived at.
The re ticu loendothe lia l c e ll typ ifie d  by the splenocyte catabolizes 
haemoglobin at a re la t iv e ly  constant ra te . I t  also releases it s  iron 
at a constant ra te . This is  in agreement with previous data of Noyes 
and coworkers (1960). The iron is  transported across the ce ll membrane 
as ferrous iron. Ex tra ce llu la r ly  i t  undergoes redox state change to 
fe r r ic  iron.
This fe r r ic  iron is  taken up by either transferrin  or a non-transferrin 
iron binding mechanism. This non-specific ity  of binding is  in keeping 
w ith  previous work from th is  laboratory showing the absence of a 
sp ec ific  apotransferr in-macrophage interaction  (Baynes et a l , 1987b). 
A fe r r ic  chelator is  also able to gain access to the released iron.
The ra te  of release of iron from the splenocyte is  not modified by a 
saturated transfe rrin . The reason for th is  may re la te  to the well 
documented re la t iv e  lack of transferrin  receptors on tissue macrophages
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(Hamilton et a l,  1984). The rate of release can be increased by 
increasing extrace llu la r unsaturated iron binding capac ity . P r io r 
transfusion, by moving more iron through the reticu loendothe lia l ce ll 
is  able to enhance splenocyte iron storage capacity.
D ife r r ic  t ra n s fe r r in  re s u lt in g  from splenocyte iron release then 
undergoes t is su e  s p e c if ic  d is t r ib u t io n  in  d ir e c t  r e la t io n  to 
t ra n s fe r r in  recepto r density on tissues, with the major rec ip ien t 
tissue being the erythroid marrow. Non-transferrin iron (re leased 
largely in the setting of saturated transferrin) is  rap id ly  cleared by 
the hepatocytes. F e rr it in  release from splenocytes and uptake by 
hepatocytes may contribute to the spleen to liv e r c ir c u it  in animals 
with a saturated transfe rrin . F e rr it in  has been shown to contribute to 
the c i r c u i t  between the spleen and the l iv e r  in  circumstances 
associated with red c e ll breakdown, but it s  quantitative sign ificance 
is  not clear (Siimes and Dallman, 1974). Once the iron reaches the 
liv e r i t  is  retained there in the setting of a saturated transferrin . 
This d ifference between the hepatocyte and reticu loendothe lia l ce ll in 
the handling of iron in the setting of a saturated transferrin  may 
r e la te  to the w ell developed t ra n s fe r r in  receptor system on the 
hepatocyte (Page et a l , 1984; Trinder et a l , 1986). The mechanism 
whereby transfusion increases re ticu loendothe lia l iron storage capacity 
and whereby a saturated transferrin  increases hepatocyte iron storage 
capac ity  more than l ik e ly  invo lves increased in t ra c e llu la r  iron 
e ffecting  a s h if t  of cytoplasmic fe r r it in  mRNA to the polyribosomes by 
the iron responsive element (Aziz and Munro, 1986; Rogers and Munro,
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1987; Hentze et a l , 1987; Leibold and Munro, 1988; Casey et a l , 
1988; Dickey et a l , 1988).
The apparent d iscrepancy between the cu rren t data and those of 
Bergamaschi and co-workers (1986) in re la tio n  to increased transferrin  
saturation increasing splenocyte iron retention may re la te  to these 
worker's use of infused iron which supersaturated the animals sera and 
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